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The treatment of tuberculosis (TB) is challenging – its etiological agent, 
Mycobacterium tuberculosis (Mtb), is intrinsically resistant to the majority of antibiotics 
normally effective against other bacterial pathogens, and the ones that demonstrate efficacy 
against Mtb require prolonged treatment durations to eliminate the pathogen from the host. 
Current treatment regimens result in toxic side-effects for many patients and often lead to 
patient non-compliance, which contributes to treatment failure and the development of 
drug-resistant TB. Consequently, there is a pressing need for the development of a shorter 
therapeutic regimen, as well as a better understanding of the factors limiting the 
effectiveness of current drugs. Transposon insertion sequencing (TnSeq) is a high-throughput 
methodology using next-generation-sequencing to quantify bacterial mutant phenotypes en 
masse. In this dissertation, we describe the use of TnSeq to address two different questions 
related to the problem of stress resistance in Mtb, in particular antibiotic resistance. 
The first problem was determining the functional role of mycobacterial acid 
resistance protease (MarP), a protein necessary for tolerance of not just acidic environments 
but also oxidative, detergent and antimicrobial stresses. Using a TnSeq-based genetic 
interaction screen, we identified genes that could be functionally related to marP. Our screen 
indicated that MarP had parallel functionality to multiple proteins involved in cell envelope 
biosynthesis and remodeling, suggesting a role for MarP in these processes. We also 
identified a few genes that could be functionally antagonistic to marP, possibly by promoting 
 increased cell envelope permeability to substrates. The loss of marP also alleviated fitness 
defects resulting from mutations in the ESX-5 secretion system, the mycobactin biosynthesis 
pathway and rv0812, a previously uncharacterized gene. Characterization of rv0812 indicated 
that its main function was in para-aminobenzoic acid (PABA) biosynthesis, and that the loss 
of marP might promote activity of a bypass pathway to rv0812. 
In a second study, we screened for mutants with altered susceptibility to rifampicin, 
ethambutol, isoniazid, vancomycin and meropenem. Through TnSeq, we were able to 
identify and rank genes mediating antibiotic susceptibility in Mtb. Multiple cell envelope 
mutants were predicted to be strongly sensitive to the drugs tested, whereas inactivation of 
individual efflux pumps did not appear to contribute majorly to drug sensitivity. We also 
identified fecB as a gene contributing to cross-sensitivity toward all five antibiotics – 
characterization of the ΔfecB mutant indicated that it had a more permeable cell envelope 
and was attenuated for growth in vivo and on solid media. 
Together, the data from the two screens implicate the cell envelope to be a major 
determinant of Mtb resistance toward antibiotic and in vivo stresses, and suggest the 
existence of a functionally-linked cluster of cell envelope genes that could be synergistic 
targets supplementing current antibiotic regimens.  
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CHAPTER 1: INTRODUCTION 
1.1 Tuberculosis – global and historical perspectives 
Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis 
(Mtb), a slow-growing facultative intracellular bacterium. TB is a major global health problem 
today, being the leading cause of mortality due to infectious disease alongside HIV/AIDS – in 
2014, the death tolls of TB and HIV/AIDS were estimated to be 1.5 million and 1.2 million 
respectively, with 0.4 million deaths resulting from co-morbidity from both diseases. There 
were approximately 9.6 million new TB cases in 2014, contributing to a global total of 13 
million cases (WHO, 2015). The problem has been further compounded by the emergence of 
multidrug-resistant (MDR) strains, which are resistant to the two frontline drugs isoniazid 
and rifampicin, and require regimens with more expensive and toxic antibiotics, but with 
prolonged treatment times and increased treatment failure rates. 
1.1.1 From pre-history to the age of microbiology 
Mtb is an obligate pathogen with Homo sapiens being its exclusive host, which 
reflects the long history of co-evolution of both species since the dawn of humanity. 
Phylogenetic analyses suggest the Mtb emerged around 70,000 years ago and began its 
global spread with the migration of hunter-gatherer populations out of Africa, and flourished 
as a consequence of increased human population densities during the Neolithic period 
(Comas et al., 2013). While it was originally believed that Mtb may have originated from 
zoonotic transmission, recent phylogenetic analyses suggest that mycobacterial strains 
causing non-human mammalian TB have in fact diverged from the major human strains. Mtb 
has branched into seven lineages, with the East-Asian Lineage 2 and the Euro-American 
Lineage 4 accounting for the large majority of TB cases in the world (Brites and Gagneux, 
2015). These lineages have been demonstrated to be more virulent in animal models and are 
implicated in faster progression to active disease relative to the other lineages (Coscolla and 
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Gagneux, 2014); of particular, the Beijing family of strains within lineage 2 exhibit 
hypermutability (Ford et al., 2013) and a greater tendency to acquire mutations conferring 
drug resistance and also compensatory mutations mitigating the fitness costs associated with 
drug resistance (Casali et al., 2012; Merker et al., 2015). 
Mtb has thrived in the midst of human civilization and left its mark on human history 
– TB has been well-documented since antiquity, going by multiple names including 
consumption, the ancient Hebrew schachepheth, the Greco-Roman pthisis, the Classical 
Chinese 癆, the Medieval Anglo-French scrofula/king’s evil, and the Great White Plague of 
17th century Europe (Daniel, 2006; Daniel and Daniel, 1999). Befitting of the moniker “the 
Great White Plague”, TB was responsible for 20% of the adult deaths in Europe and North 
America between the 17th and 19th centuries (Wilson, 2005). A major turning point in 
humanity’s struggle with TB was the discovery of its causative agent Mycobacterium 
tuberculosis in 1882 by Robert Koch(Koch, 1952), paving the way for directed therapies 
against the pathogen. Following Koch’s discovery were advances such as the diagnostic 
Mantoux test and the partly efficacious Bacille Calmette Guérin (BCG) vaccine; however, TB 
therapy was largely limited to surgical intervention and the improved nutrition and bed rest 
afforded by the prolific TB sanatoria of the time(Riva, 2014). It was only with the advent of 
anti-TB antibiotics that humanity could finally push back against the TB epidemic. 
1.1.2 The rise and decline of TB chemotherapy 
The early 20th marked the start of the age of antimicrobial chemotherapy, beginning 
with Paul Ehrlich’s “magic bullet” of the anti-syphilitic arsphenamine and followed by the 
discovery and eventual mass production of sulfonamides and penicillin between 1930 and 
the 1940s. The realization of TB chemotherapy lagged behind slightly - after an initial misstep 
in 1925 with the non-effective and toxic gold-based compound sanocrysin, the first two 
drugs effective in controlling TB were discovered almost simultaneously in 1944 (Riva, 2014); 
streptomycin was isolated from Streptomycin griseus by Selman Waksman and Albert 
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Schatz(Schatz et al., 1944), whereas para-aminosalicylic acid (PAS) was synthesized by Jörgen 
Lehmann in collaboration with the Swedish pharmaceutical Ferosan (Lehmann, 1964). They 
were subsequently followed by the discoveries of the current front-line TB drugs 
isoniazid(McDermott, 1969), rifampicin(Sensi, 1983), ethambutol (Doster et al., 1973) and 
pyrazinamide (HKCS, 1981) between 1950 to the 1970s, which reduced treatment duration 
from 24 to 6 months, and multiple other compounds currently employed as second-line TB 
drugs. This golden age of TB drug discovery led Waksman, who had won the Nobel Prize in 
1952 for his discovery of streptomycin, to optimistically declare that “the complete 
eradication of the disease is in sight”(Waksman, 1964). 
Progress in anti-TB chemotherapy has however been closely shadowed by the 
development of drug resistance. The initial clinical trial of streptomycin was promptly 
followed by a report of streptomycin resistance developing in 12 out of 13 individuals within 
a treatment group (Crofton and Mitchison, 1948). It was subsequently shown that co-
administration of streptomycin with PAS improved cure rates and reduced the development 
of antibiotic resistance(Jamieson, 1950), setting the standard of multi-drug regimens in the 
treatment of TB. The implementation of combination drug therapy could however only delay 
the inevitability of drug resistance – isoniazid resistance increased from 6.3% to 9.7% in 
newly reported cases of TB in the US between 1961 and 1968 (Steiner et al., 1970), and 
multiple outbreaks of multidrug-resistant (MDR) TB  made their appearance in the 1970s  
(Keshavjee and Farmer, 2012). Despite this trend, development and innovation of novel anti-
TB drugs and drug regimens had already begun to taper off (the next novel anti-TB drug 
TMC207/bedaquiline would only be approved 40 years later (Diacon et al., 2012)). The rise of 
MDR-TB, the growing HIV epidemic and also the increasing prevalence of diabetes (Restrepo 
and Schlesinger, 2014) led to a resurgence in TB cases in the 1980s, leading the World Health 
Organization to declare TB to be a global health emergency in 1993. The return of TB was 
only held in check with the aggressive implementation of the directly observed treatment, 
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short-course (DOTS) strategy combining an easily accessible, standardized treatment 
regimen with a comprehensive system of monitoring encompassing case detection, diagnosis 
and the evaluation of treatment outcomes, improving patient compliance and treatment 
success rates (WHO, 2010). 
TB mortality has fallen 47% since the 1990s; however, the threat of MDR-TB is still 
ever-present, accounting for an estimated 480,000 cases worldwide, of which only 50% were 
successfully treated globally (WHO, 2015). The last decade has also seen the emergence of 
extensive drug-resistant (XDR) TB, defined as MDR TB with additional resistance to at least 
one fluoroquinolone and a second-line injectable (amikacin, capreomycin or kanamycin) – an 
estimated 9.7% of MDR-TB cases are also XDR. The prognosis for XDR-TB is even poorer than 
that of MDR-TB – a global study of a cohort of 2,685 XDR-TB patients between 2012 to 2015 
saw only 2.6% completing treatment successfully (WHO, 2015).  The poor treatment 
outcomes of MDR and XDR TB are a major hurdle in the complete eradication of the disease, 
and necessitate the development of novel, efficacious anti-TB antibiotics. 
1.2 The challenges of TB treatment 
TB is a particularly challenging bacterial disease to treat – Mtb is intrinsically resistant 
to the majority of antibiotics normally effective against other bacterial pathogens (Morris et 
al., 2005; Nguyen and Pieters, 2009), and the ones that demonstrate efficacy against Mtb 
require prolonged treatment durations to eliminate the pathogen from the host. The so-
called “short-course” HRZE (isoniazid, rifampicin, pyrazinamide and ethambutol) regimen for 
drug-sensitive TB needs at least 6 months, whereas more complicated cases of multidrug-
resistant (MDR) and extensively-drug-resistant (XDR) TB require the additional use of second-
line drugs for an extended duration of 18 months and beyond (WHO, 2010). Consequently, 
there is a pressing need for the development of novel, more effective anti-TB drugs, and also 
shorter therapeutic regimens. 
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The list of ideal characteristics for novel anti-TB drugs is extensive – these include 
potent bacteriocidality against both replicating and non-replicating bacteria, extended 
pharmacokinetic duration, synergistic effects with other anti-tubercular drugs, low toxicity, 
oral activity and novel mechanisms of action refractory to the development of resistance 
(Protopopova et al., 2007). While a large extent of anti-tubercular drug design is a problem of 
medicinal chemistry, rational prioritization of effective drug targets within the physiology of 
Mtb and a clear understanding of the processes limiting the effectiveness of current 
antibiotics would definitely accelerate the development of novel antibiotics and antibiotic 
regimens. The recalcitrance of Mtb in the face of chemotherapy results from the complex 
interplay of its privileged niche within the host environment and its unique bacterial 
physiology, which will be discussed in detail in this section. 
1.2.1 Mtb and the host 
Mtb is transmitted via aerosol infection, with an infectious dose as small as a single 
infectious droplet (estimated to contain between 1-10 bacilli) capable of causing disease 
(Riley, 1957; Russell et al., 2010); the lung being the primary site of infection, pulmonary TB 
represents 70-90% of TB cases, with possible extrapulmonary manifestations resulting from 
dissemination of Mtb to other organ systems including the lymph nodes, bones/joints and 
central nervous system.  Upon inhalation, Mtb is taken up by professional phagocytes in the 
airways – in addition to its primary host cell, the alveolar macrophage, Mtb can also reside in 
neutrophils, monocytes and dendritic cells (Ernst, 2012; Kang et al., 2011; Wolf et al., 2007). 
As an intracellular pathogen, Mtb is able to survive and replicate in phagosomal 
compartments within the resting macrophage by inhibiting phagolysosomal fusion and 
phagosomal acidification (Armstrong and Hart, 1971; Goren et al., 1976). The onset of 
adaptive immunity occurs 4-6 weeks post-infection in humans  (Wolf et al., 2007), leading to 
macrophage activation and promoting phagolysosomal fusion and acidification (MacMicking 
et al., 2003). While replication is inhibited, Mtb is nonetheless able to survive the multitude 
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of stresses within the phagolysosome, including acidification, the production of reactive 
oxygen/nitrogen species, hypoxia, and nutrient limitation (Ehrt and Schnappinger, 2009; 
Vandal et al., 2008). 
Granuloma formation is a defining feature of Mtb infection. In basic pathology, a 
granuloma is simply defined as an organized aggregation of macrophages, however, this 
definition fails to capture the cellular and structural complexity as well as the dynamic nature 
underlying the TB granuloma. The TB granuloma is an evolving structure built by successive 
waves of immune cell migration – phagocytosis of Mtb by alveolar macrophages triggers 
chemokine production, attracting a variety of innate immune cells including neutrophils, 
monocyte derived macrophages, NK cells and γδ T-cells. With the induction of adaptive 
immunity, the granuloma becomes more well-defined, consisting of a central core of infected 
macrophages surrounded by a peripheral cuff of lymphocytes. The later stages of granuloma 
development may be accompanied by macrophage differentiation into multinucleated 
Langhans giant cells, epitheloid cells or foamy cells, cellular necrosis in the center of the 
granuloma and  the formation of a capsule of fibroblasts around the granuloma, which 
contributes to the containment of the infection (Ehlers and Schaible, 2012). There is a large 
degree of granuloma heterogeneity even within a single host (in humans and also the 
complex granuloma-forming animal models such as the rabbit, guinea pig and non-human 
primates), ranging from fully cellular granulomas composed of macrophages, neutrophils and 
lymphocytes to “caseous” granulomas with a necrotic center(Lenaerts et al., 2015), with 
great variability in microenvironmental conditions such as oxygen tension, nutrient 
availability, pH and oxidative/nitrosative stress, and also in the ability to contain and sterilize 
Mtb infection (Lin et al., 2014). While Mtb is commonly thought to be an intracellular 
pathogen, large numbers of extracellular Mtb have been observed to reside in the necrotic 
foci of caseous granulomas (Hoff et al., 2011; Orme, 2014); the microenvironmental 
variability between the intracellular and extracellular compartments within a granuloma 
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further adds to the environmental heterogeneity that the Mtb population faces within the 
host. 
 The immune response of the host to Mtb is a double-edged sword – while generally 
able to contain Mtb infection, it can also inadvertently create an environment that nurtures 
and shields the pathogen. Containment of Mtb infection is generally quite effective – it is 
estimated primary infection with Mtb results in latent TB 90% of the time without 
therapeutic intervention, with active TB developing in only the minority of the cases. Most 
cases of adult TB result from reactivation a long time after the primary infection, 
representing a loss in ability of the immune response to contain the latent infection; this is 
exemplified by the increased risk of TB reactivation in HIV/AIDS patients due to depletion of 
CD4+ T cells, and also in patients undergoing therapeutic neutralization of TNF (Ernst, 2012).  
Conversely, the host immune response complicates TB chemotherapy; as mentioned 
previously, the large degree of heterogeneity between environmental niches occupied by 
Mtb in the host may impose differential adaptive pressures on the pathogen, resulting in 
physiologically distinct subpopulations varying in susceptibility to antibiotic stress (Dartois 
and Barry, 2013; Lenaerts et al., 2015). The fact that Mtb resides in the granuloma and the 
macrophage led to early speculation that these structures may be a major physical barrier to 
antibiotic penetration, facilitating chemotherapeutic evasion and the development of drug 
resistance (Crofton and Mitchison, 1948). On a cellular level, the macrophage can act as a 
permeability barrier – higher concentrations of rifampicin (but not isoniazid and ethambutol) 
were required to kill Mtb within macrophages as opposed to extracellular Mtb(Hartkoorn et 
al., 2007).  Early clinical studies also indicated that rifampicin and isoniazid concentrations 
were lower in tuberculous lung lesions relative to the levels in blood plasma (Canetti et al., 
1969; Kislitsyna and Kotova, 1980). Recent mass-spectrometry (MS)-based studies of drug 
distribution in the rabbit model of Mtb infection have shed further light on this issue – 
distribution varies between drugs, with moxifloxacin showing favorable partitioning into lung 
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tissue and granulomas, while levels of isoniazid, rifampicin and pyrazinamide were 
substantially lower in tuberculous lesions relative to blood plasma (Kjellsson et al., 2012); 
drug distribution was particularly poor in the center of necrotic granulomas, reflective of the 
absence of vascularization and active transport in this acellular zone, and of the TB drugs 
tested, only pyrazinamide was able to diffuse effectively through the caseum(Dartois, 2014). 
This observation could partially account for the observation of “persister” Mtb populations in 
caseous granulomas that are recalcitrant to chemotherapy (Lenaerts et al., 2007; Lin et al., 
2013). In summary, TB chemotherapy is hindered by the inaccessibility of its resident niches 
to antibiotics; however, this it but the first of the hurdles preventing antibiotic access to its 
targets in Mtb. 
1.2.2 The physiology of Mtb and antibiotic resistance 
Antibiotic resistance can be classified into two categories – acquired resistance, in 
which the bacterium gains resistance by the acquisition of genes via horizontal transfer or 
spontaneous mutation within its genome that can transmitted vertically to subsequent 
generations, and intrinsic resistance, in which the bacterial species in general already 
possesses insensitivity to certain antibiotics prior to encounters with the relevant antibiotic 
selection pressures (Cox and Wright, 2013). Both classes of resistance are important in the 
context of TB chemotherapy. Mtb is exceptional amongst bacterial pathogens in terms of 
intrinsic resistance, with many common classes of antibiotics being ineffective against the 
pathogen, limiting the chemotherapeutic arsenal against Mtb to a few specialized anti-
tubercular drugs. This problem of intrinsic resistance is further compounded by that of 
acquired resistance; while Mtb has not been reported to acquire resistance via horizontal 
transmission in a clinical setting, the aforementioned problems of extended 
chemotherapeutic duration and patient non-compliance have created an environment 
conducive to the selection of antibiotic resistant clinical strains just from spontaneous 
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mutation alone. This subsection examines the various aspects of the physiology of Mtb 
contributing to both intrinsic and acquired resistance. 
1.2.2.1 The mycobacterial cell envelope  
The mycobacterial cell envelope is a central player in determining antibiotic 
susceptibility in Mtb, being a target for multiple first and second-line anti-tubercular drugs, 
and also acting as the major barrier limiting accessibility of antimicrobial compounds to their 
targets within the mycobacterium. The uniquely-structured cell envelope is a hallmark 
feature of mycobacteria as well as other members of the bacterial suborder 
Corynebacterineae - while phylogenetically classified as gram-positive bacteria, the 
Corynebacterineae possess a complex multi-layered cell envelope that distinguishes it from 
both Gram-positive and gram-negative bacteria. This cell envelope can be subdivided into 
three main layers: the plasma membrane, an inner mycolic acid-arabinogalactan-
peptidoglycan (mAGP) core, and an outer capsular layer (Brennan, 2003; Kaur et al., 2009). 
The plasma membrane is a phospholipid bilayer similar to that of other bacteria, and is 
surrounded by the core mAGP complex – closest to the plasma membrane is the surrounding 
peptidoglycan layer, which is covalently linked to an arabinogalactan layer, which forms 
multiple ester linkages with α-alkyl, β-hydroxy (C60-C90) mycolic acids, resulting in a 
covalently-attached mycolic acid layer. This mycolic acid layer intercalates with non-
covalently attached lipids and lipoglycans to form a lipid bilayer commonly referred to as the 
mycobacterial outer membrane – these include the phthiocerol dimycoserates (PDIMS), 
phosphatidylinositol mannosides (PIMs), phenolic glycolipids (PGLs), mannosylated-
lipoarabinomannan (ManLAM) and acyltrehaloses. The outer membrane and plasma 
membrane thusly encompass the periplasmic space (Bansal-Mutalik and Nikaido, 2014; 
Brennan, 2003; Hoffmann et al., 2008; Jackson, 2014; Kaur et al., 2009). Exterior to the outer 
membrane is the mycobacterial capsule, a detergent-soluble layer primarily comprised of 
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polysaccharides and proteins with low amounts of lipids (Daffe and Etienne, 1999; Jackson, 
2014; Sani et al., 2010) 
The mycobacterial cell envelope is a thick and highly hydrophobic structure, and is 
exceptional amongst the various bacterial cell envelopes in their impermeability to 
exogenous substrates and antibiotics. Early work in Mycobacterium chelonei established that 
the permeability coefficients for hydrophilic substrates including glucose, glycine, leucine and 
glycerol were approximately 10 and 1000-fold lower than Pseudomonas aeruginosa   (P. 
aeruginosa) and Escherichia coli (E. coli) respectively (Jarlier and Nikaido, 1990).  Permeability 
coefficients for β-lactam drugs were 100-fold lower in Mtb relative to E. coli, demonstrating 
the importance of cell envelope impermeability in intrinsic antibiotic resistance (Chambers et 
al., 1995). The relation between cell envelope integrity and intrinsic antibiotic resistance has 
been further highlighted by studies in mycobacterial cell wall mutants. Mycobacterial 
mutants deficient in mycolate biosynthesis (e.g. kasB and virS-mymA operon mutants) 
exhibit increased permeability and sensitivity to antibiotics including rifampicin, 
chloramphenicol, isoniazid, pyrazinamide and ciprofloxacin (Gao et al., 2003; Liu and Nikaido, 
1999; Singh et al., 2003), whereas a Mycobacterium smegmatis mutant in fbpA, which 
catalyzes the biosynthesis of trehalose dimycolates, was observed to be hypersensitive to 
multiple broad-spectrum antibiotics and anti-tubercular drugs (Nguyen et al., 2005). 
It has been noted that lipophilic antibiotic classes such as the macrolides, 
fluoroquinolones and rifamycins are more likely to effectively penetrate the highly 
hydrophobic mycobacterial cell wall to reach their targets; comparisons between compounds 
of the same antibiotic class indicate that the more lipophilic derivatives demonstrate a higher 
inhibitory activity against mycobacteria (Brennan and Nikaido, 1995; Danilchanka et al., 
2008; Sarathy et al., 2012). This passive transport of hydrophobic substrates across the cell 
envelope is limited by cell envelope thickness and fluidity of the mycobacterial outer 
membrane – increased levels of the trans- isomeric form of mycolic acids resulting from 
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increased incubation temperatures was associated with lower outer membrane fluidity and 
permeability to the lipophilic agents norfloxacin and chenodeoxycholate(Liu et al., 1996a). 
 Recent work in the last decade have shed light on the mechanisms facilitating the 
diffusion of hydrophilic substrates (including antibiotics) across the mycobacterial outer 
membrane. In gram-negative bacteria, influx of hydrophilic substrates across the outer 
membrane is largely facilitated by porins, which are transmembrane proteins forming a beta-
barrel structure around an open water-filled channel; while substrate specificity can be 
partially governed by pore and channel size and charge, porins represent a major route by 
which antibiotics can cross the gram-negative outer membrane (Nikaido, 2003; Pages et al., 
2008). Mycobacterial porins were first identified in M. smegmatis – the protein MspA was 
shown to form stable oligomers with high channel-forming activity (Niederweis et al., 1999), 
and homology searches within the M. smegmatis genome led to the further discovery of 
three more mspA –like porin genes, accordingly named mspB, mspC and mspD . Studies of 
mspA and mspC deletion mutants as well as Mtb and M. bovis BCG strains heterologously 
expressing mspA further confirmed the role of the MspA-like porins in the transport of 
hydrophilic solutes; with mspA/mspC deletion linked to increased antibiotic MICs, and mspA 
expression resulting in accelerated growth and increased antibiotic susceptibility in Mtb and 
M. bovis BCG (Danilchanka et al., 2008; Stahl et al., 2001; Stephan et al., 2004). 
MspA-like porins are absent from the genomes of Mtb and other slow-growing 
pathogenic bacteria, and the identity of Mtb porins and hydrophilic substrate transportation 
mechanisms is less certain. The Mtb protein OmpATb/Rv0899 was previously postulated to 
be a porin based on its homology to the E. coli porin OmpA (Senaratne et al., 1998), however, 
structural studies indicated that it does not form the typical transmembrane β-barrel 
structure typical of porins, but rather a mixed α/β structure with a hydrophobic core and 
polar/acidic exterior, making it unlikely to be a transmembrane channel (Teriete et al., 2010). 
Functional characterization of OmpATb identified a functional role in surviving under acid 
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stress by rapid extrusion of ammonia to neutralize environmental pH levels; OmpATb 
expression was however unable to complement a permeability defect to the hydrophilic 
substrates serine, glycerol and glucose when expressed in an M. smegmatis mspA mutant, 
indicating that OmpATb is not likely to be a general porin.  (Song et al., 2011). Recent efforts 
have focused on the identification of outer membrane proteins that could possibly serve as 
channels for hydrophilic solutes (Rana et al., 2014; Song et al., 2008) – MctB/Rv1698 was 
shown to localize to the outer membrane and could complement the deletion of mspA in M. 
smegmatis, restoring sensitivity to ampicillin and chloramphenicol and increasing 
permeability to glucose (Siroy et al., 2008); later work demonstrated increased accumulation 
of copper as well as increased susceptibility to copper toxicity in an Mtb mutant lacking 
MctB, suggesting a role in copper efflux (Wolschendorf et al., 2011).  
Another outer membrane channel protein CpnT was shown to be involved in uptake 
of glycerol and glucose, as well as a variety of both hydrophilic and hydrophobic antibiotics in 
M. bovis BCG (Danilchanka et al., 2015; Danilchanka et al., 2014); the Mtb ΔcpnT mutant 
however exhibited a phenotypically-weaker defect in the uptake and utilization of 
glucose/glycerol, and no significant changes in antibiotic susceptibility. In addition to its 
functionality as a channel, CpnT possesses a secreted C-terminal domain that functions as a 
necrosis-inducing exotoxin by hydrolyzing NAD (Danilchanka et al., 2014; Sun et al., 2015).  
While the hunt for possible porins or porin-like proteins is still ongoing, it is plausible that the 
uptake of hydrophilic substrates may be facilitated not by dedicated porins/porin-like 
channels, but rather an extensive, highly redundant network of multifunctional proteins 
similar to the ones discussed here. 
1.2.2.2 Efflux pumps 
The permeability barrier of the mycobacterial cell envelope only provides partial 
protection against the influx of antibiotics; in the absence of a mechanism eliminating 
intracellular antibiotics, equilibration of drug concentrations across the cell envelope would 
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eventually be achieved despite the reduced influx rate. This elimination of intracellular 
antibiotics may occur via drug metabolism and degradation, or by the active efflux of 
antibiotics back into the extracellular domain (Jarlier and Nikaido, 1994). Bacterial efflux 
pumps can be categorized into five main superfamilies distinguished by their structures, 
substrates and energy sources – the ATP-binding cassette (ABC) transporter superfamily, the 
major facilitator superfamily (MFS), the small multidrug resistance (SMR) superfamily, the 
resistance-nodulation-cell division (RND) superfamily and the multidrug and toxic 
compounds extrusion (MATE) superfamily. Efflux is an active process requiring an energy 
source, with the ABC superfamily utilizing ATP hydrolysis and the other classes relying on the 
transmembrane proton-motive force (PMF) or Na+/H+ electrochemical gradient. (Pule et al., 
2016; Viveiros et al., 2012). 
The Mtb genome encodes multiple putative efflux pumps, representing most of the 
efflux superfamilies apart from the MATE superfamily (Black et al., 2014; Viveiros et al., 
2012). The role of efflux pumps in intrinsic antibiotic resistance in mycobacteria was first 
demonstrated by the M. smegmatis efflux pump LfrA (Liu et al., 1996b) – LfrA overexpression 
resulted in reduced intracellular accumulation of norfloxacin and increased norfloxacin 
resistance, while disruption of the lfrA genes reduced the MIC of ethidium bromide and 
acriflavine by 8-fold, and the MIC of ciprofloxacin, doxorubicin and rhodamine by two-fold (Li 
et al., 2004; Sander et al., 2000). The Mtb genome lacks an lfrA homolog, and 
fluoroquinolone resistance in Mtb may be mediated by other efflux pumps such as Rv1634 
and Rv2686c-2688c (De Rossi et al., 2002; Pasca et al., 2004). Since LfrA, multiple studies 
have shown an association between efflux pump overexpression/disruption on antibiotic 
susceptibility, upregulation of putative efflux pumps in Mtb under antibiotic stress as well as 
an effect of efflux pump inhibitors on antibiotic sensitivity; these studies are exhaustively 
discussed in recent comprehensive reviews (da Silva et al., 2011; Pule et al., 2016; Viveiros et 
al., 2012). 
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The role of efflux pumps in intrinsic antibiotic resistance in Mtb has however not 
been conclusively established, and a few questions remain. Given the broad specificity of 
efflux pumps, it is difficult to determine whether the observed antibiotic sensitivity or 
reduced accumulation is due to drug efflux or the defective secretion of another 
physiologically important substrate. Multiple putative pumps such as the P55 MFS 
transporter (Rv1410c), Rv1747 and MmpL7/MmpL8 have been implicated in the export of 
cell envelope components such as mycolic acids, triacylglycerides, and phthiocerol 
dimycocerosate (pdim) (De Rossi et al., 2002; Domenech et al., 2005; Martinot et al., 2016; 
Spivey et al., 2013) , and the essentiality of certain efflux pumps in the absence of antibiotic 
selection such as EfpA, MmpL3 and Rv2477c (Griffin et al., 2011) suggest key physiological 
roles  independent of antibiotic efflux. The extent of efflux-mediated antibiotic resistance 
also shows variability across mycobacteria species and strains – while there was evidence 
suggesting resistance resulting from fluoroquinolone efflux in drug resistant Mtb strains 
(Escribano et al., 2007; Louw et al., 2011), intracellular concentrations of fluoroquinolones, 
rifamycins and linelozid were unaffected in the drug-sensitive H37Rv laboratory strain upon 
treatment with the efflux inhibitors verapamil and reserpine in a separate study (Sarathy et 
al., 2013). In addition to basic gene overexpression/deletion studies and antibiotic 
susceptibility testing, quantitative methods measuring antibiotic accumulation and uptake, 
as well as comprehensive multi-strain studies are needed to conclusively establish the 
importance of efflux in antibiotic resistance. 
1.2.2.3 Metabolism of antibiotics 
The chemical deactivation of antibiotics is a principal strategy in bacterial 
antimicrobial resistance. In addition to the previously-mentioned cell envelope 
impermeability, Mtb is able to further blunt the effect of β-lactam antibiotics via the action 
of β-lactamases (Chambers et al., 1995; Flores et al., 2005). The main β-lactamase of Mtb is 
BlaC, which possesses strong broad-spectrum activity and is able to hydrolyze even 
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carbapenems (Voladri et al., 1998). The importance of this mechanism of intrinsic resistance 
to β-lactamase antibiotics has been demonstrated by the potentiating activity of β-lactamase 
inhibitors such as clavulanic acid under in vitro, in vivo and clinical settings (Flores et al., 
2005; Kumar et al., 2012; Segura et al., 1998; Tiberi et al., 2016). Mycobacteria may also 
neutralize antibiotics by chemical modification – M. fortuitum and M. smegmatis have been 
shown to encode an aminoglycoside 2’N-acetyltransferase (AAC), conferring resistance to the 
aminoglycoside antibiotics dibekacin, gentamicin, netilmicin and tobramycin (Ainsa et al., 
1996). Mtb and M. leprae possess AAC homologs, and structural comparisons indicate the 
the Mtb AAC may have a secondary role in mycothiol biosynthesis(Vetting et al., 2003). 
A few key anti-tuberculars are prodrugs requiring enzymatic activation by Mtb, and 
mutations resulting in a loss of this activation are highly represented in drug-resistant clinical 
strains. These include mutations in katG and its negative regulator furA in the case of 
isoniazid resistance (Hazbon et al., 2006; Ramaswamy et al., 2003; Vilcheze and Jacobs, 
2007), the activator ethA and its regulator ethR for ethionamide resistance(Brossier et al., 
2011; Morlock et al., 2003), pncA, which activates pyrazinamide (Konno et al., 1967; Scorpio 
and Zhang, 1996) and the dihydrofolate synthase folC, which activates PAS (Chakraborty et 
al., 2013; Zheng et al., 2013) 
1.2.2.4 Target modification 
Apart from chemical neutralization, another central theme of bacterial antibiotic 
resistance is the mutation of antibiotic targets rendering them less susceptible to antibiotic 
binding and action. Mutations in drug target genes are common in drug-resistant clinical 
strains of Mtb, and have been extensively documented and reviewed (Da Silva and Palomino, 
2011; Nguyen, 2016). As antibiotic targets generally represent essential processes in bacterial 
physiology, mutations in these genes are commonly associated with a fitness cost 
manifesting as a reduction in growth, virulence or transmission (Andersson, 2006). A case in 
point is rifampicin resistance resulting from missense mutations in rpoB, the gene encoding 
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the β-subunit of RNA polymerase. Given the central role of RNA polymerase on transcription, 
rifampicin-resistant clinical strains with mutations in rpoB exhibit extensive transcriptional 
changes (Bisson et al., 2012; de Knegt et al., 2013) and an altered metabolic profile  
characterized by  a reduction in mycobactin siderophore and sulfolipid biosynthesis (Lahiri et 
al., 2016), which may account for observed fitness costs in vitro (Billington et al., 1999; 
O'Sullivan et al., 2005). The fitness costs of rpoB mutation can be mitigated by the acquisition 
of secondary compensatory mutations, as demonstrated by secondarily-mutated clinical 
strains with a restored competitive fitness in vitro and a higher prevalence globally (Comas et 
al., 2011); fitness costs are also determined by strain genetic background and may account 
for increased rates of drug resistance in certain strains such as the Lineage 2 Beijing strain 
(Gagneux et al., 2006). Drug target mutations do not always come with a fitness cost – the 
K42R mutation in the ribosomal protein RpsL that confers streptomycin resistance is not 
attenuated in vitro, and its high prevalence clinically suggests a minimal impact on in vitro 
fitness (Bottger et al., 1998; Sander et al., 2002). Drug targets that have a higher fitness cost 
associated with mutation to resistance may thus prove to be more attractive for antibiotic 
lead development. 
While target modification is commonly associated with acquired resistance, 
constitutive modification of target proteins may function as a mechanism for intrinsic drug 
resistance. While the pathogenic species Mtb and M. bovis are intrinsically resistant to the 
macrolide and lincosamide classes of antibiotics, which bind reversibly to ribosomal RNA and 
inhibit ribosomal function, the Pasteur vaccine strain of M. bovis BCG is notably susceptible 
to these antibiotics. BCG possesses chromosomal deletions from extensive passaging of M. 
bovis under laboratory conditions, and its unique susceptibility to these ribosomal agents 
was traced to the loss of the erm37 (rv1988) gene (Buriankova et al., 2004). Erm37 
methylates 23S ribosomal RNA and reduces the affinity of the ribosomes to these antibiotics, 
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and expression of erm37 from Mtb restored macrolide and lincosamide resistance in BCG 
(Buriankova et al., 2004; Madsen et al., 2005). 
1.2.2.5 Phenotypic drug tolerance 
In addition to the intrinsic and acquired genetic factors already described, a large 
part of Mtb’s recalcitrance to chemotherapy lies in the phenomenon of phenotypic drug 
tolerance. Phenotypic drug tolerance refers to a physiological state by which the bacterium is 
able to survive exposure, but can be restored to a state of antibiotic sensitivity after in vitro 
outgrowth; in short, a state of non-heritable antibiotic resistance (Levin and Rozen, 2006). 
Phenotypic drug tolerance can be divided into two classes – class I phenotypic tolerance 
occurs in a small subset of individuals within a bacterial population before antibiotic 
exposure, whereas class II tolerance refers to a state of physiological tolerance present in the 
majority of the population, imposed by environmental conditions (Girgis et al., 2012; Nathan, 
2012; Nathan and Barry, 2015). 
Class I phenotypic tolerance (or persistence) was first described in Staphylococcus 
pyogenes – a sensitive population was subjected to penicillin treatment, and approximately 1 
in 106 bacteria survived the treatment; expansion of these survivors resulted in bacterial 
populations with the same sensitivity and proportion of survivor cells as the original parental 
population, leading to the conclusion that the resistant state was not heritable (Bigger, 
1944). This class of persistence has since been described in multiple bacterial species and 
attributed to a vast variety of mechanisms, the unifying theme being the stochastic 
regulation of gene expression. Analysis of individual Mtb cells within a replicating population 
revealed that stochastic reduction of KatG expression occurring prior to isoniazid exposure 
could account for phenotypic tolerance to isoniazid (Wakamoto et al., 2013). Mtb cells have 
also been shown to undergo asymmetric division, resulting in daughter cells with differential 
growth rates, protein distributions and antibiotic susceptibility (Aldridge et al., 2012; 
Vaubourgeix et al., 2015). Genetic screening for Mtb mutants with a higher persister 
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subpopulation identified carbon metabolism, toxin-antitoxin systems, lipid biosynthesis and 
transcriptional regulators as possible functional pathways contributing to the state of 
antibiotic persistence (Torrey et al., 2016) 
Class II phenotypic tolerance is distinguished from class I tolerance in that it occurs in 
the majority of bacteria in the population, and is induced by environmental conditions that 
limit replication (Nathan, 2012; Nathan and Barry, 2015). Class II tolerance was also first 
described in the previously mentioned Bigger study, in which the induction of bacteriostasis 
in S. pyogenes by incubation in distilled water, boric acid or lower temperatures increased 
the population of persisters toward penicillin (Bigger, 1944). Pioneering work by Wayne et al. 
showed that a gradual depletion of available O2 in liquid culture led to reduced growth and 
eventual bacteriostasis, and increased Mtb tolerance of anaerobiosis. This state was 
associated with negligible Mtb sensitivity to ciprofloxacin and isoniazid, reduced 
effectiveness of rifampicin, but also sensitization to metronidazole, which is not effective 
under replicating conditions (Wayne and Hayes, 1996; Wayne and Sramek, 1994). Since the 
Wayne model, other non-replicating (NR) Mtb models have been developed for the 
screening of anti-TB antibiotics, including the use of Mtb strain 18b, a streptomycin-
dependent mutant that undergoes replication arrest but not killing when streptomycin is 
withdrawn (Sala et al., 2010), and a multiple stress NR model combining low pH, mild 
hypoxia, nitrosative stress and low amounts of the fatty acid butyrate as a carbon source 
(Darby and Nathan, 2010; Gold et al., 2015). 
The exact mechanisms contributing to the development of class II tolerance have yet 
to be comprehensively characterized. While it is commonly held that non-replicating bacteria 
may be more resistant to antibiotic action due to reduced activity in cell envelope, nucleic 
acid and protein biosynthesis pathways, which are major processes targeted by antibiotics 
(Keren et al., 2011), other transcriptomic studies indicate a stress-dependent robust 
transcriptomic response associated with an upregulation of iron scavenging and lipid 
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biosynthesis pathways, indicating continued metabolic activity in spite of arrested growth 
that may be important in dormancy/persistence (Schnappinger et al., 2003; Voskuil et al., 
2004). As the state of class II phenotypic tolerance confers cross-resistance to multiple 
antibiotics within an anti-TB drug regimen, understanding and developing ways to 
circumvent this phenomenon will be important in the realization of rapid, effective TB 
chemotherapy. 
1.3 Genetic screening in Mtb 
The field of mycobacterial genetics was opened up by the sequencing and annotation 
of the complete Mtb genome, which spans 4.4 megabases and is comprised of approximately 
4000 genes (Cole et al., 1998). Faced with this vast catalogue of genetic information, the 
main challenge for the mycobacterial geneticist is to sift out the most interesting candidates 
for study. While the rational prioritization of study candidates is a universal problem 
common to all branches of genetics, it is one of paramount importance for a geneticist 
studying Mtb. Mtb is exceptional amongst bacteria for its intractability as a research subject 
– it has a doubling time of 18-24h and it takes 2-3 weeks for colonies to form on solid culture 
media; and its capacity for causing chronic life-threatening disease necessitates specialized 
biosafety level 3 procedures and facilities that are costly to maintain and limit the speed at 
which research can be performed. The high cost of Mtb research coupled with the inexorable 
march of time demands an efficient and accurate system for the triage of the most 
worthwhile and important genes for further study. 
A major breakthrough with regard to this problem was achieved with the creation of 
an efficient transposon mutagenesis method using a temperature-sensitive 
mycobacteriophage to deliver a highly-active Himar1- mariner transposon system (Sassetti et 
al., 2001). The high efficiency of the transposon mutagenesis system in tandem with the 
relatively unbiased nature of Himar1 transposon insertion (the Himar1 transposon inserts 
specifically into TA dinucleotide sites, of which there are ~ 75,000 in the Mtb genome) 
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permitted the creation of diverse transposon libraries approaching saturating levels of 
coverage of the Mtb genome. Additionally, the transposon insertion sites could be easily 
mapped via genetic footprinting with the appropriate PCR primers, providing a major 
advantage over other random mutagenesis methods. 
While these factors made Himar1 transposon libraries the ideal starting material for 
classical genetic screens selecting for specific Mtb mutants, the main utility of the Himar1 
system was in the genome-wide determination of gene essentiality in Mtb. In his seminal 
work, Sassetti et al. combined the transposon mutagenesis system and microarray 
hybridization to develop a methodology to identify conditionally essential genes in M. bovis 
BCG, which was accordingly dubbed transposon site hybridization (TraSH) – transposon 
mutants essential for survival under a specific condition (minimal media) were lost from the 
library, and these mutants could be determined by measuring mutant frequency in the 
library relative to a control library (rich media) via microarray hybridization (Sassetti et al., 
2001). Optimization of the technique further led to the determination of genes essential for 
in vitro growth from highly saturated Mtb transposon libraries (Sassetti et al., 2003) – the 
absence/paucity of transposon insertions in a genetic locus in a saturated library could be 
interpreted as an indication that the gene function was necessary for Mtb viability. TraSH 
was subsequently employed in the identification of genes involved in Mtb survival and 
persistence during infection (Dutta et al., 2014; Sassetti et al., 2003), adaptation and survival 
in macrophages (Dutta et al., 2014; Sassetti et al., 2003) and genes differentially required 
under conditions of fast and slow growth (Beste et al., 2009). 
The TraSH approach was expanded upon and refined with the application of next-
generation-sequencing (NGS) methods in the highly-parallel deep sequencing of transposon 
mutant libraries, yielding a series of similar experimental methodologies collectively referred 
to as transposon insertion sequencing (TnSeq) (Chao et al., 2016; Griffin et al., 2011; van 
Opijnen et al., 2009). Prior to TnSeq, analyses of essentiality by TraSH were limited by the 
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small dynamic range of microarray signals (less than 10-fold), the inability to map insertions 
to their precise locations and the need for a prefabricated microarray; these problems were 
overcome by the use of NGS, which permitted the mapping of transposon insertion sites to a 
single-base pair resolution and improved precision in the quantification of insertions in both 
coding and non-coding regions (Chao et al., 2013b; Griffin et al., 2011). Subsequent 
improvements to TnSeq methodology include a system for identifying genes possessing both 
essential and non-essential domains  (Zhang et al., 2012), random barcoding of PCR 
amplicons to correct for possible amplification biases during sample preparation (Long et al., 
2015), and an array of methods for making robust statistical calls of essentiality from TnSeq 
data (Chao et al., 2013b; DeJesus et al., 2015; DeJesus and Ioerger, 2013, 2015; DeJesus et 
al., 2013; Pritchard et al., 2014). The benefits from TnSeq screening in Mtb have yielded 
more definitive lists of genes essential for in vitro and in vivo survival (Zhang et al., 2012; 
Zhang et al., 2013). Recent efforts have focused on the use of TnSeq in genetic interaction 
screening - the identification of secondary mutations significantly modulating the phenotype 
of a primary mutant, which would imply a functional relation between the mutated genes; 
this approach has led to the discovery of the components of a membrane associated 
oxidoreductase complex involved in reactive oxidative species detoxification (Nambi et al., 
2015) and genetic factors differentially required for growth in mutants of the penicillin 
binding proteins (PBPs) ponA1 and ponA2 (Kieser et al., 2015). 
1.4 Thesis research aims 
This dissertation describes the use of TnSeq screening to answer two disparate 
problems related to the tolerance of exogenous stresses by Mycobacterium tuberculosis, 
with a particular focus on antibiotic stress. In chapter 2, we sought to identify genetic 
interaction partners of mycobacterial acid resistance protease (MarP), a protein necessary 
for the tolerance of not just acidic environments but also oxidative, detergent and 
antimicrobial stresses. Through a TnSeq-based genetic interaction screen, our goal was to 
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identify novel genes functionally related to marP in order to understand the mechanisms 
behind its role in pleiotropic stress resistance. Chapter 3 presents a series of chemical 
genomic screens aimed at finding genetic factors modulating antibiotic susceptibility in Mtb, 
with the goals of better understanding the mechanisms of intrinsic antibiotic resistance in 
the pathogen, and the possible discovery of synergistic targets potentiating antibiotic 
treatment. The study culminates in the construction and characterization of a fecB knockout 
mutant, notable for its cross-sensitivity to multiple antibiotics and attenuation in vivo. In 
addition to contributing to our understanding of mycobacterial stress resistance, this work 
attempts to lay out guidelines for the proper implementation and interpretation of TnSeq 
screens. 
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CHAPTER 2: SCREENING FOR GENETIC INTERACTION PARTNERS OF MARP 
2.1 Background 
Mtb mainly resides in the phagosomal compartment the of host macrophage, a 
hostile microenvironment that imposes a multitude of environmental stresses upon the 
pathogen. Among these stresses is phagosomal acidification – before the onset of adaptive 
immunity, phagosome-lysosome fusion of the Mtb-containing phagosome is arrested, 
resulting in a mildly acidic intraphagosomal environment of ~pH 6.2; subsequent 
macrophage activation by interferon gamma (IFN-γ) is able to overcome to overcome the 
blockade of phagolysosomal fusion, permitting the further acidification of the 
phagolysosome to ~pH 4.5 (Armstrong and Hart, 1971; Huynh and Grinstein, 2007; Ohkuma 
and Poole, 1978). In spite of macrophage activation and phagosomal acidification, Mtb is 
able to maintain its intrabacterial pH at ~ 6.76-7.5 (Vandal et al., 2008). A genetic screen of 
10,100 Mtb transposon mutants was performed to identify mutants defective in recovery 
after exposure to acidified 7H9-Tween 80 media at a pH of 4.5; 34 mutants representing 21 
different Mtb genes, of which two (rv2136c and marP) were found to be consistently 
defective in recovery from the three different types of acidified media tested (7H9-Tween, 
7H9-tyloxapol and phosphocitrate buffer at pH 4.5). The marP mutant also failed to maintain 
intrabacterial pH in activated macrophages, and was attenuated for growth in the mouse 
aerosol infection model, failing to persist during the chronic phase of infection (Vandal et al., 
2008). In addition to acidification, the marP transposon mutant was also hypersensitive to 
other stresses such as oxidative stress (Biswas et al., 2010) and multiple antimicrobial 
compounds including erythromycin, rifampicin (Vandal et al., 2008), malachite green, 
nigericin and vancomycin (Pan, unpublished).   It was also recently shown that an M. 
marinum ΔmarP mutant is similarly unable to survive phagosomal acidification and fails to 
establish infection in a zebrafish infection model (Levitte et al., 2016)  
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marP is conserved across multiple mycobacteria species including M. leprae, M. 
bovis, M. avium paratuberculosis, M. bovis and M. smegmatis  (Ribeiro-Guimaraes and 
Pessolani, 2007) and was predicted to encode a membrane associated serine protease with 
four transmembrane helices (Cole et al., 1998; Sonnhammer et al., 1998). Structural studies 
confirmed that the periplasmic domain of marP is a functional serine protease of the 
chymotrypsin family, and that the periplasmic localization of a catalytically active protease 
domain was essential for its protective function against oxidative and acid stress (Biswas et 
al., 2010; Small et al., 2013). The protease substrate/s for MarP in vivo eluded research 
efforts at identification for some time; however, recent work in our lab has identified the 
peptidoglycan hydrolase RipA as a proteolytic target of MarP. MarP was observed to cleave 
RipA in vitro and coimmunoprecipitate to a greater extent under acidic pH relative to neutral 
conditions in a M. smegmatis system expressing tagged versions of MarPTB and RipATB. 
Expression of RipA-LG (a mutant form of RipA with amino acid substitutions in its predicted 
MarP cleavage site, and was confirmed to be less efficiently processed by MarP) was unable 
to complement growth and morphological defects in a RipAB knockdown M. smegmatis 
strain, indicating that cleavage by MarP may be required to activate RipA in vivo (Botella, 
2016, study under review). 
This chapter describes a concurrent attempt to identify genetic interaction partners 
of marP by TnSeq-screening, with the aim of discovering other functionally related proteins.  
2.2 Defining genetic interaction under TnSeq 
Genetic interaction/epistasis is the phenomenon by which the effects of one gene 
are able to modulate the phenotypes arising from a second gene; more succinctly put, 
genetic interaction refers to an unexpected phenotype resulting from the combination of 
two or more mutations (Baryshnikova et al., 2013; Dixon et al., 2009). The effective 
measurement of genetic interaction requires both a quantitative indicator of phenotypic 
strength, and a neutrality function, which basically defines the “expected” baseline 
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phenotype arising from two functionally independent mutations (Mani et al., 2008). Genetic 
interactions can thus be quantified and classified into two main classes according to how the 
double mutant deviates phenotypically from the neutral baseline – negative/aggravating 
interaction refers to a case where the double mutant exhibits a more severe phenotype than 
expected, whereas positive/alleviating interactions reflect the opposite situation where the 
double mutant phenotype is less severe than the expected baseline. 
The functional relationship of a secondary unknown mutation to a primary “bait” 
mutant of interest may be inferred from genetic interaction, though accurate interpretation 
may be complicated by the pleiotropic and highly-interconnected nature of genetic 
interaction networks. Negative interactions mainly indicate a functional relationship by 
which the function of one gene buffers against the loss of the other; the most extreme case 
of negative interaction, synthetic lethality, arises when two mutations with little or no 
growth defect individually result in the unviability of the double mutant, indicative of the 
total loss of buffering capacity. Negative interaction commonly results from individual genes 
acting in parallel, redundant biological pathways fulfilling a common function; it may also 
arise in a situation referred to as a defect-damage-repair cycle, in which the loss of one gene 
leads to secondary damages which are repaired by a second gene functionally different from 
the first (Ting et al., 2008) (Fig. 2.1a). 
Positive interaction can be slightly more difficult to interpret due to the multiple 
possibilities resulting in the double mutant having a less severe phenotype than expected. 
One of the more basic subclasses of positive interaction is coequal interaction, in which the 
phenotypes of the single mutants and the double mutant are quantitatively similar 
(Baryshnikova et al., 2013); this is suggestive of the mutants being in the same biological 
pathway  - when one mutation deactivates the entire pathway, additional lesions within the 
pathway will have no additional impact on the organism. Positive interaction may also be 
indicative of suppression, by which one mutation is able to rescue the fitness defect caused 
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by another; mechanisms for suppression include the restoration of homeostatic equilibrium 
by the antagonistic effect of the secondary mutation, relief of a toxic effect caused by a 
primary mutation, or induction of a compensatory pathway (Fig. 2.1B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 – Interpretation of genetic interaction within the context of the marP TnSeq 
genetic screen.  Schematic diagrams of possible functional interactions between MarP and 
unknown interactor protein X. Shapes outlined by dashed lines denote loss-of-function 
mutation of the protein indicated. A - Negative interaction may indicate the presence of 
parallel pathways with similar functions redundant to MarP, or damage repair pathways 
compensating for deleterious secondary effects from MarP deletion.  B – Positive 
interactions may identify pathways regulated by MarP – MarP may activate functional 
proteins, and loss-of-function mutations in MarP, the activated protein or both proteins 
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should result in similar phenotypes as both proteins are in the same functional pathway. 
MarP may also negatively regulate the function of another protein, and the resultant gain of 
function from the loss of regulation may result in deleterious effects. Toxicity from the loss of 
function may be suppressed by the loss of the protein. Suppression mutations by which loss 
of function of protein X rescues the loss of MarP (or vice versa, as the relationship can be 
asymmetric or symmetric) may also indicate an antagonistic functional relationship between 
the two; loss of either protein results in homeostatic disequilibrium, which may be restored 
when both proteins are lost. 
TnSeq allows for the highly-parallel quantitative fitness analysis of mutants within a 
transposon library, and is well-suited for the purposes of genetic interaction screening by the 
comparison of transposon insertion libraries constructed in the wildtype and bait mutant (in 
this case a gene-deletion mutant of marP) backgrounds (van Opijnen et al., 2009; van 
Opijnen et al., 2014). The readout of a TnSeq analysis reports the proportional frequencies at 
each transposon mutant within the output library – mutant frequency at the end of a TnSeq 
experiment is a function of three factors -  1. the initial mutant frequency, 2. the degree of 
outgrowth of the entire population over the course of the experiment , and 3. the 
exponential growth rate of the mutant relative to the overall exponential growth rate of the 
library (Wmt) (van Opijnen and Camilli, 2013). Assuming that the majority of mutations have a 
minimal impact on fitness, and that the selection conditions of the experiment only perturb 
the fitnesses of a minority of the mutants in the library, the overall growth rate of the library 
approximates that of the parental wild-type strain it was constructed form (van Opijnen et 
al., 2009) . If factors 1 and 2 are held constant for all transposon mutants within the analysis, 
mutant frequency is correlated with the Wmt, and can be used as an index of mutant fitness – 
transposon mutants with a higher fitness and growth relative to the overall library will have 
higher frequency within the library, and conversely, low frequency or absence of the mutant 
in a library indicates reduced fitness. 
The multiplicative/product function is the most widely-accepted neutrality function 
in genetic interaction studies, and it predicts that the fitness of a double mutant to be the 
product of the fitnesses of each of the single mutants, fitness in this case being the 
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exponential growth rate of the mutant relative to the wild type (Mani et al., 2008), or 
approximately the Wmt observed from the TnSeq experiment. Under this definition of 
neutrality, a non-interacting mutant would have the same Wmt, and consequently output 
mutant frequency in both the WT and ΔmarP backgrounds, supposing initial mutant 
frequencies and the degree of outgrowth of the WT/ΔmarP libraries are equivalent. An index 
of genetic interaction for each gene can thus be derived from the log-transformed ratio of 
the transposon insertion frequencies for the gene between the ΔmarP and WT library 
background, otherwise referred to as the log2Fc: 
𝑙𝑜𝑔2𝐹𝑐 =  𝑙𝑜𝑔2 (
𝑀𝑢𝑡𝑎𝑛𝑡 𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦 𝑖𝑛 ∆𝑚𝑎𝑟𝑃 𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑
𝑀𝑢𝑡𝑎𝑛𝑡 𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦 𝑖𝑛 𝑊𝑇 𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑
) 
A negative log2-Fc indicates reduced mutant frequency in the knockout background relative 
to the WT, and hence lower-than-expected double mutant fitness/negative interaction, 
whereas a positive TnSeq-Fc indicates positive interaction. 
Possible functional interpretations of genetic interactions from the screen are 
summarized in Fig. 2-1. As the bait marP mutation is a gene deletion, and transposon 
insertions in general completely disrupt gene function (though this is not always the case); 
mutations in the context of this experiment are generally assumed to be complete loss-of-
function mutations, constraining and simplifying the possible interpretations. Negative 
interactions may indicate functional pathways redundant to MarP, or damage-repair 
pathways repairing secondary damages resulting from the loss of MarP. Of greater 
mechanistic interest are the positive interactions – as the function of MarP has been shown 
to be dependent on serine protease activity in the periplasm (Biswas et al., 2010; Small et al., 
2013), the implication is that MarP acts by regulating the activity of other proteins via 
proteolysis, and positive interactions may indicate proteolytic substrates that may be 
activated or degraded by MarP. Suppression mutations by which transposon mutation 
rescues growth defects caused by marP deletion, or vice versa, may suggest functionally 
antagonistic pathways to MarP. 
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2.3 Genetic interaction analysis using TnSeq 
In order to identify potential genetic interaction partners of MarP, we constructed 
quadruplicate Mtb transposon mutant libraries using the aforementioned Himar1 transposon 
mutagenesis system  (Sassetti et al., 2001) in both the WT H37Rv and ΔmarP backgrounds. 
After phage transduction, transposon mutants were selected for on rich Middlebrook 7H9 
solid media. 7H9 was used instead of the commonly used 7H10/11 media to avoid selective 
pressure from malachite green. It was assumed that at the point of mutagenesis, each 
possible transposon insertion site had an equal probability of transposon insertion in both 
the WT and ΔmarP backgrounds, fulfilling one of the premises necessary for the direct 
comparison of mutant frequencies between the two strains. The ΔmarP strain has a slight 
growth defect on 7H9 plates relative to the WT background; to standardize the degree of 
outgrowth between the two experimental groups, the WT and ΔmarP libraries were 
incubated for 19 and 21 days post-mutagenesis respectively before analysis/storage. The 
constructed libraries consisted of ~105 unique mutants each, suggestive of high library 
diversity. 
Libraries were sequenced via the Illumina® HiSeq platform, and transposon-
chromosome junctions were mapped to TA-dinucleotide insertion sites as previously 
described, in order to determine the respective frequencies of each transposon mutant (Long 
et al., 2015). 500,000 to 3,200,000 unique transposon insertions were mapped to the 
genome for each library, with coverage of the possible TA insertion sites ranging from 50-
70% each; after aggregation of the quadruplicates, both the WT and the ΔmarP backgrounds 
had a TA site coverage of ~78-79%, indicative of a highly-saturating coverage of non-essential 
TA sites (Table 2.1).  
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Table 2.1 - Sequencing statistics of TnSeq libraries 
Library Unique insertions mapped #TA sites hit % TA coverage 
WT1 995,189 47,768 64.0 
WT2 888,503 49,309 66.1 
WT3 3,195,442 39,441 52.9 
WT4 3,042,234 46,408 62.2 
WT total 8,121,368 58,212 78.0 
KO1 757,952 41,442 55.6 
KO2 500,802 42,315 56.7 
KO3 3,069,648 48,589 65.1 
KO4 2,455,883 52,107 69.7 
KO total 6,784,285 58,638 78.6 
Downstream TnSeq library analysis was performed using the TRANSIT analysis tool 
(DeJesus et al., 2015). Insertion counts across libraries were normalized by the trimmed-
total-reads (TTR) procedure to adjust for differences in sequencing depth and saturation 
between library samples. Insertions were then totaled for each gene, and gene-level log2Fcs 
were computed from the ratio of normalized insertion counts between the ΔmarP and WT 
backgrounds; the statistical significance of each gene-level WT/KO comparison was assessed 
by resampling under a variation of the classical permutation test , and false discovery rate 
was controlled via the Benjamini Hochberg procedure (DeJesus et al., 2015). Under a 
statistical cutoff of q<0.05, there were 194 significant negative interactors and 83 significant 
positive interactors with marP (Table 2.2, Figure 2.3A). In addition to genetic interaction 
analysis, gene essentiality was assigned using a 4-state Hidden Markov Model (HMM) 
(DeJesus and Ioerger, 2013) under each of the library backgrounds; the mean number of 
insertions per TA site per gene was also computed as a continuous quantifier of mutant 
fitness/gene essentiality in each set of libraries (Table 2.2, Figure 2.2). Genome-wide mutant 
fitness in both libraries was distributed on a long-tailed, heavy-peaked bimodal distribution 
with peaks centered at the limit of detection (representing essential genes) and the library 
mean of insertions per site; excluding essential genes, the majority of mutants displayed 
fitnesses close to the library mean (~70% of genes had mean insertion counts per TA site 
within ±2-fold of the library mean) (Figure 2.2), indicating that the mean library fitness was 
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likely to be approximately similar to the fitness of the parental strain. Approximately 12% of 
the genes in each library set were marked as essential by the HMM; the fitness distribution 
of the ΔmarP libraries was slightly longer-tailed, with 17.1% of genes classified as either 
essential/growth-defect causing and 8.4% conferring a growth advantage versus 15.1% and 
5.4% in the WT background, indicating genetic interaction between the marP deletion and 
transposon insertions (Table 2.2, Figure 2.2). 
 
Table 2.2 - Essentiality statistics of WT/ΔmarP libraries.  Gene essentiality calls from 4-state 
HMM and conditional essentiality calls from the resampling test. Gene essentiality could not 
be determined for 17 genes due to the low number of TA insertion sites in these genes. 
 
Gene essentiality (HMM) 
 WT ΔmarP 
  # genes % genes # genes % genes 
Non-essential 3188 79.0 2989 74.1 
Essential 478 11.8 493 12.2 
Growth-defect 135 3.3 197 4.9 
Growth advantage 218 5.4 340 8.4 
Undetermined 17 0.4 17 0.4 
Conditional essentiality (ΔmarP vs WT) 
  # genes % genes 
Negative interactors 194 4.8 
Positive interactors 83 2.1 
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Figure 2.2 - Transposon mutant fitness distribution in WT/ΔmarP library backgrounds.  
Histograms of distributions of mutant fitness for each gene based on the mean insertions per 
TA site per gene metric; to accommodate the long-tailed distributions, fitness is expressed as 
a log2 transformed ratio of the mean insertion count per TA site for each gene relative to the 
mean insertion count per TA site over the entire genome (~40 insertions per site after read 
normalization over all libraries). Distributions are representative of quadruplicated 
transposon libraries in the WT/ΔmarP library backgrounds, 
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Figure 2.3 – Functional categorization of genetic interaction partners of marP. A – Volcano 
plot of q-values obtained from resampling testing against TnSeq-Fc for each gene locus. 
Genes passing the significance threshold (q<0.05) are coloured based on their functional 
categories in Tuberculist, and notable genes have been labeled with their gene names. B- 
Categorical breakdown of negative and positive interactors of marP based on Tuberculist 
functional categories. Proportions of each functional category in the H37Rv Mtb genome are 
displayed alongside as a point of reference. 
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2.3.1 Negative interactors 
We identified 194 significant (q < 0.05) negative interactors of marP (Fig. 2.3A, 
Appendix A1). Based on the functional categories defined by Tuberculist, there was a notably 
higher representation of cell wall/cell process genes in the set of negative interactors 
(73/194, or 37.6%) relative to the overall proportion of cell wall/process genes in the Mtb 
genome (779/4036, or 19.3%) (Fig. 2.3B). Negative interactors within this category were 
functionally diverse, including genes involved in peptidoglycan biosynthesis/remodeling 
(pbpA, ponA1 and the short-chain Z-isoprenyl diphosphate synthase rv1086), cell division 
(ftsE, ftsX, ftsI/rv2864c, rodA), inorganic ion transport (the phosphate transport operon 
rv0928-rv0930 and sulfate transport operon rv2400c-rv2397c), substrate exporters (mmpS3, 
mmpL7, secA2, rv1410c  and the putative efflux pump operon drrABC), various lipoproteins, 
and membrane-associated proteins of unknown function.  In addition to genes formally 
classified as cell wall/cell process genes, the NlpC/P60 family peptidoglycan hydrolases ripA, 
ripC(rv2190c) and ripD(rv1566c) were identified as negative interactors of marP in the 
virulence, detoxification and adaptation functional category. 
As negative interaction implies parallel functionality and redundancy, we were 
interested in seeing which of the other 20 genes identified in the acid sensitivity screen 
alongside marP were also negative interactors (Vandal et al., 2008). 8 out of the 20 genes 
were significant negative interactors (pbpA, ponA1, ppm1, lysX, rv0955, caeA, mpa and 
rv2136c) (Table 2.3), suggesting that in addition to resistance to acidic conditions, these 
genes may also mediate parallel functions that become more essential in the absence of 
marP, resulting in synthetic sickness/lethality in the double mutant. Most of these genes fall 
under the cell wall/cell processes Tuberculist functional category with the exception of lysyl-
tRNA synthetase lysX, which may contribute to peptidoglycan peptide bridge formation, 
which has been observed in tRNA synthetases in other bacteria (Neihardt et al., 1975; Vandal 
et al., 2008; Villet et al., 2007). Among the other genes with established functions, pbpA and 
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ponA1 encodes penicillin-binding proteins involved in peptidoglycan biosynthesis and 
remodeling, whereas ppm1 encodes a polyprenol-monophosphomannose synthase involved 
in the biosynthesis of lipomannan and lipoarabinomannan. Given the predominance of 
known and putative genes involved in cell envelope biosynthesis amongst the negative 
interactors, it is likely that marP plays a role in cell envelope integrity, which could possibly 
account for its pleiotropic stress-sensitive phenotype. 
In addition to genes annotated as contributing to cell wall structure, we also noticed 
that marP was synthetically sick/lethal with multiple genes involved in sulfur utilization 
(Table 2.4). These include the primary sulfate transport complex operon (subI-
cysTWA1/rv2400c-2397c) and the sulfur metabolism genes sirA, cysD, cysH, sseA, cysG, cysN 
and the thiosulfate sulfurtransferase gene sseA. Loss of these genes (with the exception of 
sseA) results in profound growth attenuation in the WT background, as indicated by the 
HMM essentiality calls and the low mean insertions per TA site (<7 vs the library mean of 43); 
these genes became fully essential under the ΔmarP background. This may be interpreted as 
marP activating secondary sulfur transport pathways, however, it is more likely that intact 
sulfur utilization pathways are necessary for cell envelope integrity and function.  
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Table 2.3 - List of mutants hypersensitive to 7H9-Tw at pH4.5 from a prior acid sensitivity 
screen Mutant fitness is expressed in terms of mean insertions per TA site in the gene (the 
mean across the entire genome is ~43 in the WT background and ~48 in the ΔmarP 
background, post-normalization for library size). Significant q-values (q<0.05) are highlighted 
in green, while insignificant results are highlighted in yellow. Essentiality calls under the 
WT/KO library backgrounds are labeled as NE- non-essential, ES – essential, GD – growth 
defective, GA – growth advantageous. 
 
 
 
   
 
  
Rv # Gene WT ΔmarP log2FC q-val Tuberculist category Function WT Call KO call
Rv0016c pbpA 13.9 0.1 -7.73 0 Cell wall/cell processes penicillin-binding protein PbpA NE ES
Rv0050 ponA1 21.9 0.5 -5.50 0 Cell wall/cell processes
bifunctional penicillin-binding protein 
1A/1B PonA1
NE GD
Rv2051c ppm1 126.7 7 -4.19 0 Cell wall/cell processes
polyprenol-monophosphomannose 
synthase Ppm1
ES ES
Rv1640c lysX 69.7 5.8 -3.58 0 Information pathways lysyl-tRNA synthetase 2 LysX NE GD
Rv0955 rv0955 58.9 5 -3.57 0 Cell wall/cell processes integral membrane protein NE GD
Rv2224c caeA 276.4 29.9 -3.21 0 Cell wall/cell processes carboxylesterase CaeA GA NE
Rv2115c mpa 32 7.3 -2.13 0 Cell wall/cell processes mycobacterial proteasome ATPase Mpa NE GD
Rv2136c rv2136c 125.9 33 -1.93 0.0008 Cell wall/cell processes undecaprenyl-diphosphatase NE NE
Rv2206 rv2206 19.4 7.9 -1.30 0.1263 Cell wall/cell processes transmembrane protein NE NE
Rv3679 rv3679 18.8 10.3 -0.87 0.5009 Cell wall/cell processes anion transporter ATPase NE NE
Rv3680 rv3680 16.1 10 -0.69 0.3206 Cell wall/cell processes anion transporter ATPase NE NE
Rv2052c rv2052c 58.6 42.7 -0.46 0.7532 Conserved hypotheticals hypothetical protein GA NE
Rv1272c rv1272c 33.5 31 -0.11 1 Cell wall/cell processes ABC transporter membrane protein NE NE
Rv1781c malQ 78.1 79.9 0.03 1
Intermediary metabolism and 
respiration
4-alpha-glucanotransferase MalQ NE NE
Rv1273c rv1273c 28.8 39.9 0.47 0.5197 Cell wall/cell processes ABC transporter membrane protein NE NE
Rv0007 rv0007 183.6 335.1 0.87 0.08 Cell wall/cell processes membrane protein GA GA
Rv2222c glnA2 32.5 76.5 1.23 0.0037
Intermediary metabolism and 
respiration
glutamine synthetase GlnA2 NE NE
Rv2379c mbtF 7.4 19.6 1.41 0 Lipid metabolism peptide synthetase MbtF NE NE
Rv3682 ponA2 262 925.2 1.82 0 Cell wall/cell processes
bifunctional membrane-associated 
penicillin-binding protein 1A/1B PonA2
GA GA
Mean insertions 
per TA site
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Table 2.4 – Negative interactors involved in sulfur utilization 
 
Proteases that negatively interact with marP may indicate redundant regulatory 
roles, and common proteolytic substrates. We identified 5 proteases that were negative 
interactors of marP (Table 2.5). Rip1/Rv2869c is a site-2-protease (S2P) that controls multiple 
transcriptional pathways, including the regulation of lipid biosynthesis and cell envelope 
composition (Makinoshima and Glickman, 2005; Schneider et al., 2014). However, since Rip1 
acts via intramembrane proteolysis of transmembrane segments, and the protease domain 
of marP is localized to the periplasm, it is unlikely that they independently regulate a 
common substrate; sequential processing of the same protein substrate at starting with 
periplasmic cleavage followed by transmembrane proteolysis, as in the case of a site-1-
protease/S2P system, would instead be implied by positive genetic interaction. It is thus 
likely that the negative interaction from rip1 is not dependent on a shared substrate, but 
independent regulation of cell envelope integrity.  
The remaining four proteases are all membrane-associated proteins. HtpX is a 
putative heat shock protein while PepD is a HtrA-like serine protease, suggesting a possible 
role for marP in processing misfolded proteins. Rv2224c/CaeA is a membrane-associated 
Rv # Gene WT ΔmarP log2FC q-val Tuberculist category Function WT Call KO call
Rv2400c subI 4 0 -7.58 0 Cell wall/cell processes sulfate-binding lipoprotein SubI GD ES
Rv2391 sirA 3.1 0.1 -4.86 0
Intermediary metabolism and 
respiration
ferredoxin-dependent sulfite 
reductase SirA GD GD
Rv1285 cysD 3.2 0.1 -4.53 0.0025
Intermediary metabolism and 
respiration
sulfate adenylyltransferase subunit 2 
CysD GD ES
Rv2398c cysW 3.5 0.2 -4.46 0.0001 Cell wall/cell processes
sulfate-transport ABC transporter 
integral membrane protein CysW GD ES
Rv2392 cysH 3.8 0.3 -3.78 0.0027
Intermediary metabolism and 
respiration
3'-phosphoadenosine 5'-
phosphosulfate reductase CysH GD GD
Rv2399c cysT 2.5 0 -1.81 0.0027 Cell wall/cell processes
sulfate-transport ABC transporter 
integral membrane protein CysT GD ES
Rv2397c cysA1 2 0 -1.59 0.0003 Cell wall/cell processes
sulfate-transport ABC transporter ATP-
binding protein CysA1 GD GD
Rv3283 sseA 55.7 23.4 -1.25 0.0001
Intermediary metabolism and 
respiration thiosulfate sulfurtransferase SseA NE NE
Rv3778c rv3778c 0.9 0 -0.92 0.043
Intermediary metabolism and 
respiration cysteine desulfurase GD ES
Rv2847c cysG 2.2 0.1 -4.63 0.0136
Intermediary metabolism and 
respiration uroporphyrin-III C-methyltransferase GD ES
Rv1286 cysN 6.5 1.9 -1.79 0.0368
Intermediary metabolism and 
respiration bifunctional enzyme CysN/CysC GD ES
Mean insertions 
per TA site
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protease shown to be important for virulence in the mouse model of Mtb infection (Lun and 
Bishai, 2007; Rengarajan et al., 2008) and was also identified as a factor involved in acid 
resistance (Vandal et al., 2008), whereas Rv3194c is a PDZ-domain containing Lon-like 
protease. Known proteolytic substrates of these proteases include GroEL2, which is 
processed by CaeA (Rengarajan et al., 2008), and Rv2744c, which is processed by PepD and is 
classified as a member of the PspA-family of proteins involved in the phage-shock process in 
Gram-negative bacteria (White et al., 2011). These known substrates, alongside those that 
have not been identified yet, may be shared proteolytic targets of marP. 
Table 2.5 – Negatively-interacting proteases 
 
As RipA was identified by our lab to be a proteolytic substrate activated by MarP 
(Botella, study under review), it was unexpected that ripA was classified as a negative 
interactor (Fig. 2.4A), which would imply that it lies on a parallel functional pathway to marP 
as opposed to being on the same pathway. The analysis of ripA is complicated by the fact 
that RipA possesses both essential and non-essential domains as indicated by a prior TnSeq 
study (Zhang et al., 2012), and the transposon mutants detectable in the output TnSeq 
library are not complete loss of function mutants, but plausibly neutral/partial loss of 
function mutants. Mapping of the transposon insertions in ripA in the WT and ΔmarP library 
backgrounds revealed that ripA could sustain transposon insertions in its C-terminal non-
essential domain in the WT background, in agreement with the prior TnSeq study, but not in 
the ΔmarP background, indicating the domain becomes synthetically essential in the absence 
of marP. Under these special circumstances, the synthetic lethal interaction observed could 
Rv # Gene WT ΔmarP log2FC q-val Tuberculist category Function WT Call KO call
Rv0563 htpX 29.8 2.9 -3.35 0
Virulence, detoxification and 
adaptation
protease transmembrane protein heat 
shock protein HtpX NE NE
Rv0983 pepD 21.1 2.2 -3.26 0
Intermediary metabolism and 
respiration serine protease PepD NE GD
Rv2224c caeA 276.4 29.9 -3.21 0 Cell wall/cell processes carboxylesterase CaeA GA NE
Rv2869c rip1 36.3 2 -4.18 0 Cell wall/cell processes metalloprotease RseP NE GD
Rv3194c rv3194c 74.6 35.2 -1.08 0.0012 Cell wall/cell processes PDZ domain-containing protease NE NE
Mean insertions 
per TA site
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be interpreted as the combined effect of two partial loss-of-function mutations producing a 
complete loss-of-function of an essential pathway. The further implications of this ripA-marP 
genetic interaction will be discussed in detail in section 2.x 
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Figure 2.4 – Negative interaction of ripA with marP.  A – TnSeq statistics for ripA. B – 
Transposon insertion map for ripA in quadruplicated WT/ΔmarP libraries. Histogram bars 
indicate the number of unique transposon insertions sequenced at each TA site in each 
library  
  
Rv # Gene WT ΔmarP log2FC q-val Tuberculist category Function WT Call KO call
Rv1477 ripA 26.9 0.2 -7.11 5E-05
Virulence, detoxification 
and adaptation Peptidoglycan hydrolase ES ES
Mean insertions 
per TA site
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2.3.2 Positive interactors 
We also identified 83 significant positive interacting partners of marP (Fig. 2.3A) – as 
positive interaction may be the result of marP deletion alleviating the fitness defects of the 
transposon mutant, or conversely, that of the transposon mutant alleviating the marP 
phenotype, we sub-classified positive interactors based on the degree of fitness defect of the 
transposon mutant in the WT background: group 1 positive interactors had less than half of 
the library mean of insertions per TA site (<21 insertions per TA site), and were interpreted 
to be growth defective or essential in the WT background, and the positive interaction likely 
represents alleviation of the transposon mutant fitness defect; whereas group 2 positive 
interactors (>21 insertions per TA site) had minimal/no growth defects in the WT 
background, indicating that positive interaction was likely due to increased fitness of the 
double mutant relative to the parental ΔmarP strain. These groups are only approximate 
classifiers of the type of positive interaction; for example, some mutants (e.g. rv1178) have a 
low transposon count in the WT background and a higher than average insertion count in the 
ΔmarP background, suggesting that the double mutant alleviates fitness defects observed in 
both single mutants in a two-way antagonistic relationship. 
Similar to the case of negative interactors, there was an overrepresentation of cell 
wall/cell process genes amongst the positive interactors (30/83 genes, or 36.1%, relative to 
19.3% in the whole genome). Notably, genes from the type VII secretion systems ESX-1, ESX-
3 and ESX-5 were represented amongst the positive interactors (Table 2.6). Of these three 
systems, the ESX-5 genes (eccBCDE5, mycP5, rv1794) exhibited the strongest group 1 positive 
interactions (log2Fc > 5.5) – mutants exhibited strong attenuation in the WT background 
(mean insertions per TA site <= 1) but not in the ΔmarP background, with mutation of eccB5, 
eccC5 and eccE5 conferring a slight fitness advantage (mean insertions per TA site >60, 
relative to the library mean of ~48 insertions per site). The ESX-1 genes eccB1, eccCa1, 
eccCb1, espI and eccD1 exhibited weaker group 2 positive interactions – mutations in these 
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genes conferred a slight fitness advantage in the WT background (>60 insertions per TA site, 
relative to the WT library mean of 43 insertions per site), and a larger fitness advantage in 
the ΔmarP background (>100 insertions per TA site). Finally, the ESX-3 genes espG3, eccD3 
and mycP5 exhibited weak group 1 positive interaction with marP – insertions in these genes 
were not detectable in the WT background, leading to these genes being labelled as essential 
in the WT background by the HMM, but could be detected (~1 insertion per TA site) in the 
ΔmarP background, suggesting weak alleviation of the ESX-3 essentiality phenotype.  
Table 2.6 – Positively-interacting type VII secretion system genes  Rv numbers of ESX-1 
genes are highlighted in yellow, ESX-3 genes in red and ESX-5 genes in blue. 
 
 
 
As the main substrates of type VII secretion systems are PE/PPE proteins, we were 
interested in whether any of the PE/PPE genes could contribute to the positive interaction 
observed. pe19, which is associated with the ESX-5 operon, and ppe51, which is not directly 
adjacent to any of the type VII secretion operons, conferred a minor growth advantage when 
disrupted in the ΔmarP background (Table 2.7). The magnitude of this positive interaction 
Rv # Gene WT ΔmarP log2FC q-val Tuberculist category Function WT Call KO call
Rv0289 espG3 0 1 0.99 0.024 Cell wall/cell processes
ESX-3 secretion-associated protein 
EspG3 ES GD 1
Rv0290 eccD3 0 0.7 0.76 0.0151 Cell wall/cell processes ESX-3 secretion system protein EccD3 ES GD 1
Rv0291 mycP3 0 1.5 1.32 0.0064
Intermediary metabolism 
and respiration membrane-anchored mycosin MycP3 ES GD 1
Rv1782 eccB5 0.7 66.6 6.63 0 Cell wall/cell processes ESX-5 secretion system protein EccB5 GD NE 1
Rv1783 eccC5 0.5 60.3 6.91 0 Cell wall/cell processes ESX-5 secretion system protein EccC5 GD NE 1
Rv1794 rv1794 0.5 27.2 5.91 0 Conserved hypotheticals hypothetical protein GD NE 1
Rv1795 eccD5 0.4 39.3 6.47 0 Cell wall/cell processes ESX-5 secretion system protein EccD5 GD NE 1
Rv1796 mycP5 0.6 27.6 5.65 0
Intermediary metabolism 
and respiration
proline rich membrane-anchored 
mycosin MycP5 GD NE 1
Rv1797 eccE5 1 86.9 6.38 0 Cell wall/cell processes ESX-5 secretion system protein EccE5 GD NE 1
Rv3869 eccB1 79.3 139.2 0.81 0.0155 Cell wall/cell processes ESX-1 secretion system protein EccB1 NE GA 2
Rv3870 eccCa1 64.7 142.8 1.14 3E-05 Cell wall/cell processes ESX-1 secretion system protein EccCa1 NE GA 2
Rv3871 eccCb1 61.6 130.5 1.08 0.00069 Cell wall/cell processes ESX-1 secretion system protein EccCb1 NE GA 2
Rv3876 espI 65.8 103.4 0.65 0.04602 Cell wall/cell processes ESX-1 secretion-associated protein EspI NE GA 2
Rv3877 eccD1 63.2 115.4 0.87 0.00903 Cell wall/cell processes ESX-1 secretion system protein EccD1 NE GA 2
Mean insertions 
per TA site
Positive 
interaction 
group
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effect was far lower than that observed in the ESX-5 system, suggesting that the collective 
effect of defective secretion of multiple substrate by ESX-5 may account for the strong 
positive interaction observed. 
 
Table 2.7 – Positively interacting PE/PPE proteins 
 
  
marP deletion was also able to alleviate fitness defects caused by disruption of genes 
in mycobactin biosynthesis (Table 2.8). There were a lower than average number of TA 
insertions (<22) in mbtA, mbtB, mbtE, mbtF and mbtG in the WT background, and an 
approximate 2-fold increase in transposon insertions in these genes in the ΔmarP 
background. 
 
 Table 2.8 – Positively-interacting mycobactin biosynthesis genes 
 
 
Of the 20 other acid-sensitive mutants identified in the Vandal acid-sensitivity 
screen, three (mbtF, glnA2 and ponA2) were positive interactors (Table 2.4). Apart from the 
previously discussed mycobactin biosynthesis gene mbtF, glnA2 and ponA2 were group 2 
positive interactors conferring a fitness advantage to the ΔmarP mutant. Disruption of ponA2 
conferred a significant growth advantage in the WT background (262 insertions per TA site 
Rv # Gene WT ΔmarP log2FC q-val Tuberculist category Function WT Call KO call
Rv1791 PE19 36.2 93.6 1.37 0.0114 PE/PPE PE family protein PE19 NE NE 2
Rv3136 PPE51 29 84.5 1.54 0 PE/PPE PPE family protein PPE51 NE NE 2
Mean insertions 
per TA site
Positive 
interaction 
group
Rv # Gene WT ΔmarP log2FC q-val Tuberculist category Function WT Call KO call
Rv2378c mbtG 21.7 52.4 1.27 0.0353 Lipid metabolism lysine-N-oxygenase MbtG NE NE 2
Rv2379c mbtF 7.4 19.6 1.41 0 Lipid metabolism peptide synthetase MbtF NE NE 1
Rv2380c mbtE 8.1 16.1 0.99 0.0003 Lipid metabolism peptide synthetase MbtE NE NE 1
Rv2383c mbtB 13 23.9 0.88 0.0011 Lipid metabolism
phenyloxazoline synthase 
MbtB NE NE 1
Rv2384 mbtA 7.2 23 1.68 5E-05 Lipid metabolism salicyl-AMP ligase MbtA NE NE 1
Mean insertions 
per TA site
Positive 
interaction 
group
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versus the WT library mean of 43), and an even larger increase in fitness in the ΔmarP 
background (925 insertions per TA site versus the ΔmarP library mean of 48). 
Group 2 positive interactors indicate an alleviation of the marP fitness defect on 
plates, and may represent functional processes directly antagonistic to the mode of action of 
marP. To identify these processes, we focused on a list of mutants specifically conferring a 
fitness advantage in the ΔmarP background (Table 2.9). Regulatory processes possibly 
involved in the control of MarP functional antagonism include the PhoPR two-component 
system, which regulates multiple functions including respiratory metabolism, response to 
hypoxia, stress responses and the secretion of pathogenic lipids (Gonzalo-Asensio et al., 
2008), DisA/DacA, a protein with diadenylate cyclase activity (Bai et al., 2012) and MprA, a 
regulatory protein required for persistent infection in the mouse model (Zahrt and Deretic, 
2001). Many of the strongest group 2 positive interactors are membrane proteins of 
unknown function (rv0537c, rv0538, rv0012, rv1823-1825 and rv2091c) and may possibly be 
proteolytic substrates negatively regulated by MarP. We tested if Rv0537c, Rv0538 and 
Rv0012 were possible proteolytic substrates of MarP by expressing FLAG-tagged versions of 
these proteins in WT and ΔmarP and performing a Western blot using an anti-FLAG antibody 
to check for possible differences in cleavage products; however, we were unable to 
determine if there was any differential cleavage between the two strains due to non-specific 
staining and low protein expression in the case of Rv0537c and Rv0538 (Fig. 2.5). 
  
 44 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5 – Proteolysis assay of possible protein substrates negatively regulated by MarP.   
FLAG-tagged versions of Rv0012 (29.5kDa), Rv0537c (51.3kDa) and Rv0538 (56.1kDa) were 
expressed in WT and ΔmarP strains of M. smegmatis mc2155, and proteins from the cell wall 
fraction were extracted and resolved using 15% SDS-PAGE gel electrophoresis. Western blots 
were probed with fluorescent-tagged anti-FLAG antibody (green) and anti-Dlat antibody (red 
band at ~80kDa) as a loading control. 
Coequal interactors could indicate genes in the same functional pathway – such 
mutants would recapitulate the slight growth defect of the marP mutant in the WT 
background (27 insertions per TA site versus the library mean of 43) while not having any 
growth defect in the ΔmarP background. However, due to the subtle nature of this class of 
positive interaction, we were unable to identify any positive interactors that fulfilled that 
description and passed the significance cutoffs (q<0.05) under the parameters of our screen. 
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Table 2.9 - Specific group 2 positive interactors of marP. This list of group 2 interactors was 
filtered based on essentiality calls from the HMM, including only genes that were classified 
as non-essential (NE) in the WT background, and growth-advantageous (GA) in the ΔmarP 
background 
 
 
  
Rv # Gene WT ΔmarP log2FC q-val Tuberculist category Function WT Call KO call
Rv0538 rv0538 44.2 1416 5.00 0 Cell wall/cell processes membrane protein NE GA
Rv3586 rv3586 22.4 686.9 4.94 0 Conserved hypotheticals DNA integrity scanning protein disA NE GA
Rv0012 rv0012 45.3 1119 4.63 0 Cell wall/cell processes membrane protein NE GA
Rv1824 rv1824 44.6 1106 4.63 0.0001 Cell wall/cell processes hypothetical protein NE GA
Rv0537c rv0537c 73.1 1568 4.42 0 Cell wall/cell processes membrane protein NE GA
Rv2091c rv2091c 40.8 807 4.30 0 Cell wall/cell processes membrane protein NE GA
Rv1825 rv1825 68.4 1106 4.02 0 Conserved hypotheticals hypothetical protein NE GA
Rv1823 rv1823 47.6 767.5 4.01 0 Conserved hypotheticals hypothetical protein NE GA
Rv2376c cfp2 71.8 727.1 3.34 0.0376 Cell wall/cell processes antigen CFP2 NE GA
Rv3067 rv3067 79.2 738 3.22 0 Conserved hypotheticals hypothetical protein NE GA
Rv0758 phoR 56.9 446.8 2.97 0 Regulatory proteins
OmpR family two-component system 
sensor histidine kinase NE GA
Rv0062 celA1 42.1 328.9 2.97 0 Intermediary metabolism and respirationcellulase CelA1 NE GA
Rv2375 rv2375 137.6 1024 2.90 0 Conserved hypotheticals hypothetical protein NE GA
Rv0757 phoP 78.7 572 2.86 3E-05 Regulatory proteins
OmpR family two-component system 
response regulator NE GA
Rv0995 rimJ 33.7 136.4 2.02 0.0007 Information pathways
ribosomal-protein-alanine 
acetyltransferase RimJ NE GA
Rv2203 rv2203 78.5 292.9 1.90 0.0002 Cell wall/cell processes membrane protein NE GA
Rv3683 rv3683 69.5 184.1 1.41 0.0125 Conserved hypotheticals hypothetical protein NE GA
Rv0981 mprA 77.8 197.8 1.35 0.0096 Regulatory proteins
mycobacterial persistence regulator 
MPRA NE GA
Rv3870 eccCa1 64.7 142.8 1.14 3E-05 Cell wall/cell processes
ESX-1 secretion system protein 
EccCa1 NE GA
Rv3871 eccCb1 61.6 130.5 1.08 0.0007 Cell wall/cell processes
ESX-1 secretion system protein 
EccCb1 NE GA
Rv3877 eccD1 63.2 115.4 0.87 0.009 Cell wall/cell processes
ESX-1 secretion system protein 
EccD1 NE GA
Rv3869 eccB1 79.3 139.2 0.81 0.0155 Cell wall/cell processes ESX-1 secretion system protein EccB1 NE GA
Rv3876 espI 65.8 103.4 0.65 0.046 Cell wall/cell processes
ESX-1 secretion-associated protein 
EspI NE GA
Mean insertions 
per TA site
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2.4 Characterization of Rv0812 
Based on log2Fc magnitude, rv0812 was the highest ranked positive interactor of 
marP (log2Fc = 8.38) - it was strongly attenuated and possibly essential in the WT 
background (0.2 insertions per TA site) but did not a fitness defect in the ΔmarP background 
(57.7 insertions per TA site ), indicating that the deletion of marP was able to completely 
rescue the growth defect phenotype of rv0812:tn mutants (Fig. 2.5A). Rv0812 has been 
largely uncharacterized – it is annotated as a probable amino acid aminotransferase in 
Tuberculist (Cole et al., 1998) and alternatively annotated as a 4-amino-4-deoxychorismate 
lyase (ADCL) in the NCBI RefSeq database (Tatusova et al., 2016). Comparative analysis with 
blastp indicates that Rv0812 is a class IV pyridoxal phosphate dependent enzyme (PLPDE) 
superfamily member. PLPDEs are a ubiquitous class of enzymes catalyzing a large variety of 
chemical reactions, and frequently demonstrate catalytic promiscuity, with a single enzyme 
catalyzing multiple reactions; it is plausible that Rv0812 may act through multiple pathways 
as well (Percudani and Peracchi, 2003). Rv0812 expression was also upregulated during Mtb 
infection in the mouse lung, suggesting a possible role in virulence. 
  
A
 
 
B 
 
Figure 2.6 – rv0812 is a top positive interactor of marP  A – TnSeq statistics for rv0812 B – 
Protein domain identification using NCBI blastp 
ADCL (otherwise known as the para-aminobenzoate biosynthesis enzyme PabC) is 
part of the folate biosynthesis pathway in bacteria, protists, plants and fungi - the chemical 
Gene WT ΔmarP log2FC q-val Tuberculist category Function WT Call KO call
rv0812 0.2 57.7 8.38 0
Intermediary metabolism 
and respiration amino acid aminotransferase GD NE 1
Mean insertions 
per TA site
Positive 
interaction 
group
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precursor chorismate is converted to aminodeoxychorismate (ADC) by the enzymes PabA 
and PabB, and is cleaved by ADCL/PabC into para-aminobenzoate (PABA) and pyruvate; PABA 
is subsequently converted into folate by the later steps of the biosynthetic pathway (Basset 
et al., 2004; Magnani et al., 2013; Stolz et al., 2007). Rv0812 was previously expressed in a 
partially soluble form in E. coli, and demonstrated in vitro ADCL activity (Chim et al., 2011) 
The class IV PLPDE superfamily also contains the enzyme D-amino acid transaminase 
(Dat), which was first identified in Lysinibacillus sphaericus (Jones et al., 1985; Soper et al., 
1977) . Dat catalyzes the interconversion of D-amino acids by a transamination reaction: 
                   D-alanine + 2-oxoglutarate ↔ pyruvate + D-glutamate 
Both D-alanine (D-Ala) and D-glutamate (D-Glu) are components of the peptide stem of 
peptidoglycan, and are thus essential for bacterial viability (Radkov and Moe, 2014). As 
comparative protein sequence analysis indicated a high degree of similarity between Rv0812 
and the Dat of Lysinibacillus sphaericus (Table 2.10), and experimental/genetic interaction 
screen data suggested that MarP was likely to be involved in cell envelope integrity and 
function, this raised the attractive hypothesis that Rv0812 was an uncharacterized Dat 
functionally antagonistic to MarP due to its role in D-amino acid biosynthesis, and that the 
loss of marP was able to rescue the growth defect of the rv0812:tn mutant by restoring 
physiological equilibrium. 
 
Table 2.10 – Similarity of Rv0812 and Bacillus sphaericus Dat. NCBI blastp analysis using 
Rv0812 as the query protein sequence and Bacillus sphaericus genomes (taxid:1421) as the 
search set, using the PSI-BLAST algorithm Hits passing the E-value threshold are displayed.  
 
   
Description Max score Total score Query cover E value Ident Accession
D-amino-acid transaminase [Lysinibacillus sphaericus] 56.6 56.6 91% 3.00E-09 23% AOV07189.1
4-amino-4-deoxychorismate lyase [Lysinibacillus sphaericus] 46.2 46.2 86% 9.00E-06 24% AOV09010.1
MULTISPECIES: D-amino-acid transaminase [Lysinibacillus] 44.7 44.7 90% 3.00E-05 22% WP_036118799.1
D-amino-acid transaminase [Lysinibacillus sphaericus] 41.6 41.6 90% 2.00E-04 22% WP_054549929.1
D-amino-acid transaminase [Lysinibacillus sphaericus] 40.4 40.4 90% 6.00E-04 21% WP_036220927.1
D-amino-acid transaminase [Lysinibacillus sphaericus] 40 40 90% 7.00E-04 21% WP_012295709.1
D-amino-acid transaminase [Lysinibacillus sphaericus] 37.7 37.7 90% 0.005 21% WP_069513841.1
4-amino-4-deoxychorismate lyase [Lysinibacillus sphaericus] 37.7 37.7 73% 0.005 25% WP_069510861.1
D-alanine aminotransferase [Lysinibacillus sphaericus] 37.7 37.7 90% 0.005 20% WP_024363741.1
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2.4.1 Construction of Δrv0812 mutants 
To investigate if the main functional role of Rv0812 was as an ADCL or a Dat, we 
attempted to construct rv0812 knockout Mtb strains in both the WT and KO backgrounds. 
Based on the low transposon insertion count in rv0812 in the WT background and 
essentiality predictions from previous studies (Griffin et al., 2011; Sassetti et al., 2003), it 
seemed likely that rv0812 could be essential either due to its role in the biosynthesis of 
PABA, D-Glu or D-alanine. In order to culture and isolate these potentially auxotrophic 
mutants, we replaced the chromosomal copy of rv0812 in both the WT and ΔmarP strain 
with a zeocin-resistance cassette by allelic exchange/recombineering as previously described 
(Murphy et al., 2015), and plated equal volumes of each transformation onto 7H10 plates 
without or with supplementation with either PABA or a mix of D-Glu/D-Ala. The number of 
colonies isolated on each plate provided a semi-quantitative indication of the putative 
function of Rv0812 – a higher number of colonies on a supplemented plate could indicate 
metabolic rescue, but colony counts could include false positives/cointegrants from off-
target recombineering. There were slightly more candidate rv0812-deletion colonies on 
plates supplemented with PABA relative to the unsupplemented/D-amino acid 
supplemented plates (Table 2.11A) in both the WT/KO backgrounds; to confirm that this 
increase in colony counts was due to a higher number of true rv0812 knockouts being 
recovered, we screened 10 colonies from each plate for the loss of rv0812 using PCR – we 
could only isolate mutants lacking rv0812 under PABA supplementation (Table 2.11B), 
providing an early indication that the main role of Rv0812 was as an ADCL necessary in both 
genetic backgrounds. It should be noted that colony counting/isolation was performed after 
20 days of incubation post-transformation, and slow growing mutant colonies might not have 
been detected at this timepoint. Deletion of rv0812 was further confirmed in a Δrv0812 
single-knockout mutant and a Δrv0812 ΔmarP double knockout mutant via Southern blot 
analysis (Figure 2.6), and these mutants were used in downstream analysis. 
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Table 2.11 Supplementation with PABA improves rv0812 mutant isolation on 7H10 media 
A- Colony counts from transformation reactions (including a no-DNA sham transformation 
control) plated on 7H10 unsupplemented /supplemented with 1µg/ml PABA or 1 µg/ml D-
Ala/D-Glu. B – Proportion of isolated colonies lacking rv0812. 10 colonies from each plate 
were screened via PCR for the absence of rv0812 gene copies   
A  
Strain no DNA control 7H10 only 7H10 + PABA 7H10 +  
D-Ala/D-Glu 
WT 0 27 124 40 
∆marP 0 31 57 39 
B  
 
 
  
Strain 7H10 only 7H10 + PABA 7H10 +  
D-Ala/D-Glu 
WT 0/10 5/10 0/10 
∆marP 0/10 6/10 0/10 
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Figure 2.7 – Confirmation of rv0812 deletion via Southern blot.   A - Southern blot strategy 
showing organization of the rv0812 genomic region and probe-binding /SacII digestion sites  
B – Southern blot analysis of WT, Δrv0812 and ΔmarP Δrv0812 strains. Genomic DNA was 
digested with SacII. 
2.4.2 Rv0812 is involved in PABA biosynthesis but is not essential for in vitro viability 
To confirm that the main role of Rv0812 was as an ADCL involved in PABA 
biosynthesis, we performed growth assays of the WT, ΔmarP, Δrv0812 and ΔmarP Δrv0812 
strains in unsupplemented 7H9 liquid media and 7H9 supplemented with PABA or D-Ala/D-
Glu. In spite of the implied essentiality of Rv0812 in the earlier mutant construction phase, 
both the Δrv0812 and ΔmarP Δrv0812 mutant strains were able to grow in the absence of 
PABA supplementation. However, the Δrv0812 single mutant exhibited a partial growth 
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defect in the absence of PABA supplementation relative to the other strains, suggesting a 
requirement for Rv0812-dependent PABA biosynthesis for optimal growth; this growth 
defect was not apparent in the ΔmarP Δrv0812 strain, which was agreement with the 
prediction from the TnSeq screen that marP is a positive interactor of rv0812, and that the 
loss of marP was able to rescue growth defects associated with the deletion of rv0812 (Fig. 
2.7A). In order to account for the possibility that Rv0812 non-essentiality was due to 
PABA/folate precursor carryover from the preculture, we passaged the Δrv0812 and ΔmarP 
Δrv0812 strains twice to allow for the depletion of these metabolites. While the growth 
defect became slightly more pronounced after subsequent passages, both strains were able 
to grow after two passages, with the Δrv0812 mutant exhibiting slower growth (Fig. 2.7B). 
The growth defect of the Δrv0812 mutant could be complemented by the expression of 
rv0812 under the control of the hsp60 promoter from an integrative plasmid (Fig. 2.7C)  
As 7H9 media contains bovine serum albumin, which may contain trace amounts 
folate precursors, we next investigated the growth of the Mtb strains under the metabolite-
defined Sauton’s medium. Similarly, rv0812 was not essential for growth in Sauton’s media, 
and the Δrv0812 but not the ΔmarP Δrv0812 strain exhibited a growth defect in the absence 
of PABA supplementation; this suggested that rv0812 was not essential for in vitro growth in 
liquid media (Fig. 2.8) 
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Figure 2.8 – rv0812 is required for optimal growth but is not essential in 7H9 media.  A – 
Growth of WT and deletion mutant strains in 7H9 without or with supplementation with 
PABA or D-Glu/D-Ala. OD580 values are plotted on a linear scale to emphasize the mild growth 
defect B – Growth of Δrv0812 and ΔmarP Δrv0812 after repeat passaging in unsupplemented 
7H9. The first passage culture was started at an OD of 0.05 from a mid-log phase 
unsupplemented 7H9 culture, and subsequently passaged again at D8 to an OD of 0.01. C – 
Growth of WT, Δrv0812 and complementation strain in 7H9 with or without PABA 
supplementation. Cultures were started from mid-log phase precultures grown in the 
absence of PABA supplementation. 
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Figure 2.9 – rv0812 is not essential for growth in defined Sauton’s media. Growth curves of 
WT, Δrv0812 and complementation strains in Sauton’s media with or without PABA 
supplementation. Cultures were started from mid-log phase precultures grown in Sauton’s 
media without PABA supplementation  
 In light of the observed non-essentiality of rv0812 in liquid media, we plated out 200 
cfu each of the Δrv0812 and ΔmarP Δrv0812 cultures on 7H9 agar to determine if rv0812 was 
essential on solid media, as implied by the difficulty in isolating rv0812 knockouts in the 
earlier mutant construction step. Both mutants exhibited a growth defect in the absence of 
PABA supplementation, however, small colonies could be visualized by D30 post-plating, with 
the ΔmarP Δrv0812 double mutant showing better growth than the Δrv0812 mutant. (Fig. 
2.9) 
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Figure 2.10 – rv0812 is required for optimal growth on solid media, but is not essential. A – 
Growth of Δrv0812 and ΔmarP Δrv0812 colonies. ~200 cfu of each strain was plated on 7H9 
agar plates with or without agar supplementation. Colonies shown are from D30 post-
plating. B – Close-up of unsupplemented 7H9 plate showing small Δrv0812 Mtb colonies D30 
post-plating 
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2.5 Discussion 
2.5.1 The functional role of Rv0812 
The marP genetic interaction screen identified a total of more than 200 negative and 
positive interacting partners – from this extensive list of candidates, rv0812 was chosen for 
follow-up study as 1. it was the highest ranking positive interactor, implying a strong 
functional relationship with marP, 2. it was predicted to be an essential gene, suggesting high 
physiological importance and relevance as a drug target, and 3. it seemed to have a plausible 
direct mechanistic link to marP and cell envelope function, based on the possibility that it 
was a D-amino acid aminotransferase. Characterization of the Δrv0812 mutant however 
indicated that rv0812 was not an essential gene under multiple in vitro conditions and that 
its main physiological role was as an ADCL, and was thus unlikely to contribute directly to D-
amino acid biosynthesis and peptidoglycan structure. In agreement with the predictions of 
the genetic interaction screen, marP deletion was able to alleviate the growth defect 
resulting from the loss of rv0812. 
One would expect Rv0812/ADCL to be essential given the importance of folate 
biosynthesis for Mtb viability. Previous studies in the related Actinobacteria species 
Corynebacterium glutamicum and Streptomyces sp. FR-008 have however shown that 
deletion of pabC/ADCL does not result in loss of viability but rather a growth defect, similar 
to what we have observed in Mtb (Stolz et al., 2007; Zhang et al., 2009). A possible 
explanation for this non-essentiality may lie in the highly labile nature of ADC, which 
undergoes spontaneous decomposition to PABA even in the absence of an enzyme (Tewari et 
al., 2002), providing sufficient PABA to support slower bacterial growth. Alternatively, ADCL 
activity could be facilitated by secondary promiscuous activities of other enzymes, possibly 
other PLPDEs. At this point, it is unknown how marP deletion can alter the requirement for 
Rv0812 for optimal growth – the loss of marP may affect cell envelope structure and alter 
physiological conditions within the cytoplasm (e.g. pH, ionic concentration) that may further 
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destabilize ADC, generating a higher PABA concentration; alternatively, the gene expression 
profile may be altered in the ΔmarP mutant, and enzymes fulfilling secondary bypass 
pathways to Rv0812 may be upregulated. Further metabolomic, transcriptomic and TnSeq 
interaction studies with rv0812 may reveal the nature of this bypass pathway. 
While our characterization of Rv0812 does not necessarily disprove the possibility 
that it may have secondary D-amino acid aminotransferase activity, the growth defect 
observed in the Δrv0812 mutant was PABA-dependent and not rescuable by 
supplementation with D-Glu/D-Ala, indicating that the main role of Rv0812 was not as a Dat 
but an ADCL. Additionally, alanine racemase (Alr) and glutamate racemase (MurI) are both 
predicted to be essential in this study and prior studies (Sassetti et al., 2003; Zhang et al., 
2012), suggesting that racemization is the main biosynthetic pathway for D-amino acids and 
that D-amino acid transamination is insufficient to compensate for the loss of either of the 
racemases. Dat activity, either through Rv0812 or another uncharacterized enzyme, is 
unlikely to be physiologically important in Mtb. In retrospect, our hypothesis that Rv0812 has 
a major role in D-amino acid metabolism was perhaps wishful overfitting of weak structural 
evidence in order to establish a functional link between Rv0812 and cell envelope function.  
2.5.2 The functional role of MarP 
Inferring the specific functions of MarP is by no means an easy task given the 
disparate functions of the multiple interacting partners identified; nevertheless, there are a 
few functional themes among these interactors that may provide clues about its role in Mtb 
physiology, and possibly the nature of its uncharacterized interacting partners. Many of the 
characterized genetic interaction partners of MarP have known functions in cell envelope 
biosynthesis and function, and the implication is that MarP also contributes to cell envelope 
integrity as well. Admittedly, cell envelope integrity is determined by multiple 
interconnected functional pathways, and the conclusion that MarP fulfils parallel or 
redundant functions to these cell envelope genes is a vague one that sheds little light on its 
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specific role; MarP negatively interacts with genes involved in peptidoglycan biosynthesis 
and structure, mycolic acid synthesis and secretion, lipoarabinamannan biosynthesis and 
inorganic ion transport amongst many others, and there is not enough current evidence to 
pinpoint which of these particular functions is controlled by MarP. 
Notable amongst the negative interactors was the peptidoglycan hydrolase RipA, 
which was identified in our lab to be a proteolytic substrate activated by MarP (Botella, study 
under review). As a protein with both essential and non-essential domains (Zhang et al., 
2012), RipA violates the general rule of thumb that transposon insertion results in a complete 
loss of protein function, and the ripA:tn mutants present after the initial outgrowth on 7H10 
plates are probably partial loss of function mutants. The ripA-marP interaction may thus be 
interpreted as a special case of negative interaction on the same pathway, by which the 
combined effect of two partial-loss of function mutants result in complete loss of function in 
the pathway, and hence synthetic lethality (Baryshnikova et al., 2013). This raises the 
secondary question as to why marP deletion, resulting in the complete loss of function of 
MarP, can be considered as a partial loss of function mutation in the context of the screen. A 
possible explanation is that MarP only has a partial contribution to RipA activation, and RipA 
may be activated by a second protease, or may have partial activity in the absence of 
proteolytic activation (Fig 2.10) -  while a few studies have indicated that RipA is a zymogen 
requiring activation (Chao et al., 2013a; Ruggiero et al., 2010), a contrasting report showed 
that full length RipA was capable of degrading small synthetic  peptidoglycan fragments, and 
N-terminus truncation simulating cleavage did not improve enzymatic activity (Both et al., 
2011). Secondly, while the marP deletion mutant is viable in vitro, ripA cannot be fully 
deleted due to one of its domains being essential, indicating that RipA retains at least part of 
its essential function in the absence of MarP. 
A further complication of this model arises when one considers the possibility that 
MarP may have multiple substrates, and may modulate separate parallel pathways that are 
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synthetically lethal with each other. Under this case, the combined effect of marP deletion 
with transposon insertion in the non-essential domain of RipA does not necessarily result in 
the complete loss of function of the RipA functional pathway, however, synthetic lethality 
may result from the loss of function of one of the other MarP-dependent pathways parallel 
in functionality to RipA (Fig. 2.11B). The multiple possible explanations of the ripA/marP 
negative interaction illustrate the difficulty in interpreting genetic interactions when certain 
key assumptions are violated, in this case the assumptions that transposon insertion results 
in a complete loss of gene function, and that MarP only regulates one proteolytic substrate, 
which is in turn regulated only by MarP. 
A                                                             B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.11 – Multi-activator/multi-substrate models of MarP/RipA negative interaction.  
A- RipA may be independently activated by multiple proteins including MarP, or may possess 
basal activity in the absence of proteolytic activation. Loss of MarP results in a partial loss of 
function in the RipA pathway, which may be aggravated to the point of synthetic lethality by 
a partial loss of function transposon mutation in ripA. B- MarP may activate multiple 
functional pathways parallel to that of RipA. While the loss of MarP does not necessarily 
result in lethal loss of function in the RipA pathway, loss of activity in MarP-activated parallel 
pathways may be synthetic lethal with any partial loss of function mutations in the RipA 
pathway.  These two models are not mutually exclusive, and RipA may be activated by 
multiple proteases, which in turn activate multiple functional pathways.  
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The loss of marP is able to alleviate fitness defects caused by loss of function of 
multiple pathways, as seen from the group 1 positive interactions with Rv0812, the type VII 
secretion pathways (especially ESX-5) and mycobactin biosynthesis. The marP-dependent 
alleviation of growth defects associated with the loss of ESX-5 components mirrors a 
previous study by which overexpression of the mycobacterial porin MspA, or loss of pdim in 
M. marinum was able to rescue ESX-5 essentiality. The proposed model for this phenomenon 
was that ESX-5 may be necessary for the secretion of proteins involved in the transport of 
substrates across the outer membrane, and that the increase in cell envelope permeability 
resulting from the loss of pdim or porin overexpression is able to facilitate compensatory 
diffusion of substrates into the cell (Ates et al., 2015). Similarly, marP deletion may increase 
cell envelope permeability, rescuing ESX-5 essentiality; this mechanism could potentially also 
facilitate compensatory iron transport in the absence of mycobactin, accounting for the 
positive interaction observed. While these interactions represent downstream effects of 
marP deletion and do not directly illuminate the specific functions of marP, they show that 
marP may be an important determinant of cell envelope permeability, with far reaching 
effects on other aspects of Mtb physiology. 
  Group 2 positive interaction indicates transposon mutations that can alleviate the 
fitness defects of the ΔmarP mutant, possibly revealing antagonistic functional pathways to 
MarP. While we were unable to determine if any of the group 2 positive interactors are 
proteolytic substrates of MarP, they may prove to be important determinants of cell wall 
structure – as the evidence thus far suggests that MarP is important in maintaining low cell 
envelope permeability, these group 2 interactors may have the opposite effect of promoting 
permeability. 
2.5.3 Limitations of TnSeq-based interaction screens 
As previously noted, we were unable to identify any coequal interactors (signifying 
proteins on the same functional pathway as MarP) under the conditions of our screen, given 
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the subtle nature of that class of positive interaction. The libraries in this experiment were 
constructed on rich, minimally selective 7H9 agar media to preserve library mutant diversity 
for downstream experiments; in order to better identify coequal interactions, future TnSeq 
interaction screens should use libraries constructed on media imposing a stronger selective 
pressure on mutants in the MarP functional pathway, such as higher malachite green 
concentration in the case of 7H10/7H11 media, or concentrations of antibiotics partially 
inhibitory to the ΔmarP strain, but not the WT strain. 
A core weakness of screens relying on transposon mutant libraries is that essential 
genes are not represented in the output libraries, and their absence constitutes a critical 
blind spot in the screen. The RipA-MarP negative interaction could be visualized due to the 
presence of non-essential domains in RipA; however, other fully-essential genes that could 
interact with MarP may have been overlooked. The same limitation applies to any other 
TnSeq genetic screen seeking to identify specific functional partners of the query gene, and 
future experimenters need to bear in mind the possibility that the main interacting partners 
that they are searching for might not be present in their output datasets due to gene 
essentiality. 
Finally, while it is relatively straightforward to perform a TnSeq screen and obtain 
long lists of genetic interaction partners, the true difficulty lies in the meaningful 
interpretation of the results. TnSeq ultimately measures mutant fitness, but unexpected 
changes in mutant fitness do not necessarily guarantee that the hits identified are pertinent 
to the specific function of the query gene. This is clearly illustrated in the case of our MarP 
interaction screen – MarP interacts with many different pathways with disparate 
mechanisms, but it is still unclear from the genetic interaction screen data which of these 
proteins may be a proteolytic substrate of MarP. The difficulty of interpreting the MarP 
genetic interaction screen may be attributed to its pleiotropic phenotype – it presumably 
controls cell wall permeability and integrity, which in turn affects multiple aspects of Mtb 
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physiology such as cell division, stress susceptibility and substrate transport across the cell 
envelope, resulting in downstream genetic interaction across a wide variety of pathways. 
Additionally, as cell envelope structure is controlled by multiple Mtb genes, trying to identify 
the specific process regulated by MarP becomes a task akin to finding a leaf hidden in a 
proverbial forest. 
As TnSeq screens are by nature mechanistically agnostic, meaningful interpretation 
of TnSeq data demands additional context about the problem being addressed. In the case of 
marP, the TnSeq screen may be complemented by a second protein interaction screen - 
while both types of screen have a tendency to generate non-specific hits, focusing on hits 
shared between the screens may improve the chances of identifying a true functional 
partner of MarP. Similar to what has been done before in E. coli (Babu et al., 2011), 
aggregation of genetic interaction data from multiple screens with different query genes may 
allow researchers to chart the genetic interaction network of Mtb; such networks may help 
indicate which genes are specific to certain functional pathways and which have pleiotropic 
effects, allowing for a more comprehensive interpretation of TnSeq interaction data. 
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CHAPTER 3: SCREENING FOR GENES DETERMINING ANTIBIOTIC SUSCEPTIBILITY 
3.1  Design and interpretation of a TnSeq-based antibiotic susceptibility screen 
As intrinsic resistance mechanisms play an important role in the recalcitrance of Mtb 
to chemotherapy, we performed an antibiotic susceptibility screen to identify genes that may 
contribute to these processes, in particular the ones conferring the greatest effect to 
antibiotic susceptibility. We used a preconstructed WT Mtb transposon library (WT1) for this 
set of screens,  the WT library was comprised of ~105 unique mutants and had a high library 
diversity with ~64% of the TA sites represented (Table 2.1). Glycerol stocks of this library 
were thawed and recovered in a preculture to log-phase growth, and were exposed to 
varying concentrations of the frontline antibiotics rifampicin, isoniazid, ethambutol and the 
peptidoglycan-targeting antibiotics vancomycin and meropenem. Antibiotic concentrations 
resulting in partial reduction of the overall library growth rate to 60-75% that of the 
antibiotic-free control were used in follow-up analyses (Fig. 3.1B). 
Competitive outgrowth for a period of approximately 6.5 generations (100-fold 
expansion of the population) resulted in altered transposon mutant frequencies in the 
respective output libraries (Fig. 3.1A). Antibiotic susceptibility was quantified by comparing 
mutant frequency differences between the partially-inhibited library relative to the antibiotic 
free control; similar to the genetic interaction study, we used the TRANSIT analysis tool to 
calculate the log2Fc between the libraries and determine statistical significance of the fold-
changes by resampling testing. 
Interpretation of the TnSeq antibiotic-susceptibility screen is considerably more 
straightforward than that of the genetic interaction screen. While the MarP interaction 
screen aims to indirectly infer possible functional relationships between marP and other 
genes based the observed fitnesses of single and double mutants, the antibiotic-
susceptibility screen directly answers the primary question as to which mutants exhibit the 
greatest fitness changes under antibiotic selection. Mutants with negative log2Fcs have 
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reduced fitness under antibiotic selection and are thus more sensitive, whereas positive 
log2Fcs indicate increased antibiotic resistance in the corresponding mutants. The screen 
does not directly address the mechanisms for the change in antibiotic susceptibility – it may 
be due to functional interaction between the antibiotic and gene (similar to functional 
pathway interaction observed in the genetic interaction screens), but can also occur because 
of altered repair pathway functionality, changes in antibiotic target accessibility and 
differences in drug metabolism (Fig. 3.2). 
 
Figure 3.1 – Identification of genes associated with antibiotic susceptibility by TnSeq 
screening. A -Schematic of the antibiotic sensitivity screen. Briefly, an aliquot of a saturated 
transposon library is recovered to log-phase growth, and this input library is inoculated into 
media with or without a partially inhibitory concentration of antibiotic. Outgrowth in the 
absence/presence of antibiotic results in altered transposon mutant proportions in the 
output libraries, which can be determined via sequencing and analysis. B – Partially-
inhibitory antibiotic selection of transposon libraries. Growth curves displayed are 
representative of the growth kinetics of transposon libraries observed in the presence or 
absence of antibiotic selection 
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Figure 3.2 – Genetic factors determining antibiotic susceptibility in Mtb. A – Genes may 
buffer against/enhance the effects of antibiotic target inhibition by mediating functions 
parallel or antagonistic to that of the target. B – Repair/stress response pathways can 
mitigate secondary damages caused by target inhibition. C – Antibiotic target accessibility 
may be affected by changes in cell envelope permeability or active efflux of antibiotic 
molecules. D – Antibiotic activity can be modified by enzymes activating/degrading 
antibiotics. 
3.2 Comparison of antibiotic susceptibility gene profiles indicates high similarity 
between the intrinsic resistance mechanisms of rifampicin and vancomycin 
After calculating log2Fcs and performing resampling testing on triplicated 
experimental datasets, we identified 251 mutants whose change in fitness under antibiotic 
selection was statistically significant after false discovery rate correction (q<0.05) under at 
least one of the antibiotic selection conditions tested. Cluster analysis was performed on the 
different antibiotic susceptibility gene profiles to determine which antibiotics were most 
similar in terms of their intrinsic resistance mechanisms; we expected antibiotics with similar 
modes of action (e.g. cell envelope biosynthesis) to have similar susceptibility gene profiles. 
Unexpectedly, the vancomycin and rifampicin library profiles clustered closely together, 
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subsequently clustering with the meropenem profiles followed by the ethambutol profiles 
(Fig. 3.3). The isoniazid profiles were extant to those of the other four antibiotics. 
 
 
 
Figure 3.3 – Cluster analysis of antibiotic sensitivity profiles.  Hierarchical clustering was 
performed on antibiotic sensitivity profiles derived from triplicated experiments, using 
Pearson’s correlation as the similarity metric. The mean log2 TnSeq Fc in transposon mutant 
frequency for each gene under antibiotic selection relative to the antibiotic-free control is 
indicated on the colour scale, with increased mutant representation in red and reduced 
representation in blue. Genes that did not exhibit statistically significant differences (q<0.05 
based on resampling testing) in transposon insertion under any of the antibiotic selection 
conditions tested were omitted, and the 251 remaining genes were used in this analysis 
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We compared the overlap of susceptibility-causing mutants in each of the antibiotics 
in order to identify intrinsic resistance mechanisms shared between the various antibiotics. 
Several mutations were observed to lead to increased sensitivity to multiple antibiotics (Fig. 
3.4A) – 17 genes were linked to increased sensitivity in at least 4 out of the 5 antibiotics 
tested, and transposon insertions in the fecB gene were predicted to result cross-sensitivity 
to all five antibiotics.  
To further determine the similarity of the mechanisms conferring intrinsic resistance 
to different antibiotics, we measured the overlap of sensitive mutants in one to one 
comparisons of each antibiotic; overlap was quantified by the number of genes shared 
between two sensitivity profiles and also the Jaccard index, which measures the proportional 
overlap between the two sets (A∩B/A⋃B) (Fig. 3.4B). In agreement with the clustering 
analysis, there was a large degree of overlap between the vancomycin and rifampicin 
sensitive mutant subsets, with 47 genes in common between the vancomycin and rifampicin 
sensitive mutants (proportional overlap = 0.43). There was slightly less overlap between the 
sensitive mutant subsets of rifampicin and meropenem, with 34 genes shared between the 
rifampicin and meropenem subsets (proportional overlap = 0.32); despite the fact that 
meropenem and vancomycin both target peptidoglycan as their mechanism of action, 
overlap between their sensitive mutant subsets was comparatively more modest (31 genes, 
proportional overlap = 0.26).  The ethambutol sensitivity subset overlapped more with the 
vancomycin subset (31 genes, proportional overlap = 0.32) than with the other antibiotics, 
and in agreement with the cluster analysis that the isoniazid profiles were least related to 
those of the other drugs, a smaller proportion of isoniazid-sensitive genes overlapped with 
the sensitive subsets of the other antibiotics. 
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Figure 3.4 - Intrinsic resistance mechanisms are shared between different antibiotics  A – 
Venn diagram of antibiotic sensitive mutants. Sets of significantly sensitive mutants 
(negative TnSeq-Fcs, q<0.05)  for each antibiotic are represented by the coloured regions, 
with the number of overlapping genes indicated in their respective zones. B – Overlap 
between antibiotic sensitivity profiles. Overlap matrix indicating the number of genes shared 
between pairs of antibiotic sensitivity profiles (unbracketed numbers). The degree of overlap 
is represented in the form of the Jaccard index (bracketed numbers), i.e. the proportion of 
sensitivity genes shared between the two libraries over the total number of genes from both 
libraries (A∩B/A⋃B), where A and B are different sets of sensitive mutants. 
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3.3 Validation of TnSeq predictions 
We validated the predictions of the TnSeq screen in single strain minimum-inhibitory 
concentration (MIC) assays. A panel of 21 mutant strains was selected from our strain 
collection for MIC testing (Table 3.1), consisting of a mix of mutants predicted to have 
significantly altered antibiotic susceptibility to at least one of the drugs, as well as a few 
control mutants with no significant changes in mutant representation under the TnSeq 
screen. MIC decreases of up to 20-fold were observed for vancomycin, 4-fold for rifampicin 
and meropenem, and only up to 1.8-fold for ethambutol within the panel; none of the 21 
mutants we tested displayed a detectable reduction in MIC for isoniazid (Supplementary 
Table ST1). While our TnSeq screen also indicated an enrichment for the pckA mutant under 
meropenem selection, we did not observe any significant increases in its MIC. 
The ability of the TnSeq screens to predictively rank mutants in order of antibiotic 
sensitivity was of particular interest to us as it could aid in the prioritization of study 
candidates from within the large mutant lists typically generated by genetic screens. 
Spearman correlations (ρ) between TnSeq-Fc and mutant MIC-shifts for 
vancomycin/rifampicin/meropenem were between 0.72-0.77, illustrating a general trend 
that the mutants with the lowest TnSeq-Fcs are also likely to have the lowest MICs (Fig. 
3.5B). Reflective of lower screen precision and the smaller range of MIC shifts observed for 
ethambutol, the ethambutol screen exhibited a poorer Spearman correlation (ρ=0.65). We 
were unable to determine the Spearman correlation for the isoniazid screen as none of 
mutants in our panel were isoniazid-sensitive, this could however be partly due to the 
scarcity of predicted isoniazid-sensitive mutants within our mutant panel. 
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Table 3.1 – Determination of minimum inhibitory concentrations (MICs) of a mutant strain 
panel. Determination of minimum inhibitory concentrations (MICs) of a mutant strain panel. 
Prior studies from which the respective mutants were obtained from are indicated in the 
reference column 
 
 Minimum inhibitory concentration (µg/ml) 
Strain Vancomycin Rifampicin Meropenem Ethambutol Isoniazid Source/reference 
H37Rv WT 20 0.02 7.5 0.9 0.04  
rv0007:tn 10 0.02 2.65 0.9 0.04 
(Vandal et al., 
2008) 
pbpA:tn 1.77 0.005 2.65 0.49 0.04 
(Vandal et al., 
2008) 
ΔponA1 5 0.02 7.5 0.6 0.04 Unpublished 
ΔpckA 5 0.02 7.5 0.9 0.04 
(Marrero et al., 
2010) 
rv0431:tn 2.5 0.01 3.75 0.6 0.04 
(Vandal et al., 
2008) 
Δicl1 20 0.02 7.5 0.9 0.04 
(Marrero et al., 
2010) 
Δrv0955 5 0.01 3.75 0.9 0.04 
(Goodsmith et al., 
2015) & 
unpublished 
ΔglpX 40 0.02 7.5 0.9 0.04 
(Ganapathy et al., 
2015) 
rv1272c:tn 20 0.02 7.5 0.9 0.04 
(Vandal et al., 
2008) 
ΔlprG 2.5 0.005 7.5 0.9 0.04 (Gaur et al., 2014) 
ΔepiA 20 0.02 7.5 0.9 0.04 Unpublished 
lysX:tn 10 0.01 7.5 0.6 0.04 
(Vandal et al., 
2008) 
ppm1:tn 20 0.02 7.5 0.6 0.04 
(Vandal et al., 
2008) 
Δrv2136c 20 0.02 7.5 0.9 0.04 
(Darby et al., 
2011) 
glnA2:tn 20 0.02 7.5 0.9 0.04 
(Vandal et al., 
2008) 
caeA:tn 0.88 0.0035 1.33 0.6 0.04 
(Vandal et al., 
2008) 
ΔfecB 1.25 0.005 1.88 0.9 0.04 Unpublished 
rv3679:tn 20 0.02 7.5 0.9 0.04 
(Vandal et al., 
2008) 
rv3680:tn 20 0.02 7.5 0.9 0.04 
(Vandal et al., 
2008) 
ponA2:tn 5 0.01 2.65 0.9 0.04 
(Vandal et al., 
2008) 
Δrv3717 10 0.005 7.5 0.9 0.04 Unpublished 
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Figure 3.5 – Predictive ranking of mutant antibiotic sensitivity by TnSeq. Spearman rank 
correlation (ρ) between log2Fc from the antibiotic screen and the observed log2 MIC shift 
relative to the WT strain. TnSeq Fc values are derived from triplicate experiments, while MIC 
shifts for each mutant are the mean of duplicate experiments. Mutants predicted to be 
significantly underrepresented/enriched under the TnSeq screen (q<0.05) are colored red. 
 
As the TnSeq screen assesses mutant fitness at a single antibiotic concentration, it 
does not directly measure the mutant MIC, and lowered mutant frequency within an 
antibiotic-selected transposon library does not necessarily require or imply a decrease in 
mutant MIC (Girgis et al., 2009). To verify if this was the case in the ethambutol/isoniazid 
screens, we performed growth assays of various mutants in the presence of the low 
antibiotic concentrations used in the TnSeq screens (Fig. 3.6). The fecB, rv0431, lysX, rv2224c 
and pbpA mutants displayed drastic/complete growth attenuation at an ethambutol 
concentration of 0.5µg/ml, whereas the fecB and ponA1 mutants exhibited stronger 
attenuation in the presence of 40ng/ml of isoniazid relative to the WT strain; confirming 
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reduced mutant fitness at these partially inhibitory concentrations despite the absence of a 
substantial mutant MIC shift. 
 
Figure 3.6 – Mutants predicted to be sensitive by the TnSeq screen exhibit greater growth 
attenuation at partially inhibitory antibiotic concentrations, despite minimal changes in in 
antibiotic MIC.  Growth curves of WT (black) and mutant (red) strains under A – 40 ng/ml 
isoniazid B- 0.5 µg/ml ethambutol. Growth curves are representative of two independent 
experiments 
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3.4 Identification of mutations resulting in antibiotic sensitivity and resistance 
We summarized the TnSeq data from transposon library selection under the five 
different antibiotics into a searchable annotated spreadsheet (Appendix A2). From this data, 
we identified genes that significantly affected fitness under antibiotic selection (Fig. 3.7A) – 
genes associated with particularly strong antibiotic phenotypes, cross-sensitivity to multiple 
antibiotics or have interesting functional annotations will be discussed in this section. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(continued)  
A 
 73 
 
 
 
 
Figure 3.7 – Identification and functional categorization of genes related to antibiotic 
susceptibility. A – TnSeq-Fc and false-discovery rate adjusted p values (qval) from the 
resampling test are plotted for each genetic locus, loci meeting the significance threshold of 
q<0.05 are colored according to their functional categories on Tuberculist. B – Proportions of 
sensitive/resistant mutants corresponding to the different functional categories assigned by 
Tuberculist. The overall functional composition of the Mtb H37Rv genome is displayed to the 
left of the chart as a point of reference. Data for vancomycin/rifampicin resistant mutants is 
not displayed due to the small number of genes in these groups. 
3.4.1 Cross-sensitivity to multiple antibiotics 
A rough functional classification of antibiotic susceptibility determining genes (Fig. 
3.7B) indicates that intrinsic antibiotic resistance is largely determined by genes in the cell 
wall/cell processes functional category in the Tuberculist database, comprising about 50% of 
the genes in the vancomycin, rifampicin, meropenem and ethambutol sensitive mutant sets 
B 
 74 
and 30% of the isoniazid sensitive mutant set. Many of these genes are shared across 
multiple antibiotics (Fig. 3.4B) - prominent among the genes/proteins contributing to 
antibiotic cross-sensitivity are FecB, annotated as an iron-dicitrate-binding periplasmic 
lipoprotein, Rv3267, a recently characterized LytR-CpsA-Psr (LCP) family protein that is 
capable of ligating arabinogalactan to peptidoglycan(Grzegorzewicz et al., 2016; Harrison et 
al., 2016), the protein translocase SecA2, the mannosyltransferase PimE,  and Rv2224c/CaeA, 
a cell envelope-associated carboxyesterase/protease associated with reduced virulence(Lun 
and Bishai, 2007; Rengarajan et al., 2008) and increased imipenem sensitivity when disrupted 
(Lun et al., 2014).  
We were also interested in regulatory processes involved in the control of antibiotic 
sensitivity - regulatory proteins linked to antibiotic cross-sensitivity include the protein kinase 
PknG, which was previously shown to be involved in intrinsic resistance to multiple 
antibiotics including erythromycin, vancomycin, ethambutol, rifampicin and imipenem(Wolff 
et al., 2009) , the site-2-protease Rip1, which controls transcription of multiple pathways 
including mycolic acid biosynthesis (Makinoshima and Glickman, 2005; Schneider et al., 
2014), and the uncharacterized TetR-family transcriptional regulator Rv0472c. 
3.4.2 Vancomycin, rifampicin and meropenem 
As indicated by the previously mentioned cluster analysis, the vancomycin, rifampicin 
and meropenem sensitivity profiles possess a large degree of similarity, with 25 genes shared 
between the three sensitive gene subsets; the prevalence of cell envelope genes in this 
common group suggests a strong link between cell envelope function and antibiotic 
sensitivity to these drugs. In addition to the genes previously mentioned, transposon 
insertions in ponA2, encoding a penicillin binding protein and moeA1, which encodes a 
molybdopterin biosynthesis protein were associated with increased sensitivity in all three 
drugs. 
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In contrast to the shared genes, genes that are unique to each of the susceptibility 
profiles may be indicative of mechanistic pathways specific to each drug. Transposon 
insertions in ponA1, a penicillin binding protein gene, were associated with increased 
sensitivity to vancomycin but not meropenem, highlighting that while both drugs act on 
peptidoglycan biosynthesis, they may differentially affect various functional aspects of the 
process. As to be expected, mutations in the broad-spectrum beta-lactamase gene blaC 
specifically led to increased sensitivity to meropenem but not any of the other drugs. 
Transposon insertions in the mce1 locus and the PE/PPE protein genes pe19, ppe50 and 
ppe51 were specifically enriched under meropenem selection; ppe51 mutant enrichment 
was also observed under isoniazid selection. Overexpression of PE19 was previously shown 
to result in increased cell envelope permeability (Ramakrishnan et al., 2016), which could 
possibly account for the link with meropenem sensitivity. 
3.4.3 Ethambutol 
While the ethambutol antibiotic sensitivity profile shares many common elements 
with the vancomycin/rifampicin/meropenem sensitivity cluster (e.g. genes in the pknG 
operon, fecB and pimE), the ranking of the sensitivity-related genes in this subset differ by a 
notable degree. The top ranking ethambutol sensitivity genes include ppiB, a peptidyl-prolyl 
isomerase involved in protein folding that also possesses chaperone-like activity(Pandey et 
al., 2016), fbpA, a gene involved in trehalose dimycolate/cord factor biosynthesis, the cell 
division gene rodA and the penicillin binding protein encoding gene pbpA; these mutants are 
predicted to have weaker and often statistically insignificant levels of sensitivity to 
vancomycin and rifampicin. Ethambutol resistance was also predicted for multiple 
transposon mutants involved in metabolism – we observed increased frequencies of mutants 
in carbon metabolism (glycerol kinase GlpK, polyphosphate glucokinase PpgK and trehalose-
synthase OtsA) and the putative methyltransferase HemK. 
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3.4.4 Isoniazid 
The resistance mechanisms of Mtb against isoniazid have been well-established in 
previous studies. Our screen confirmed previously reported isoniazid resistance phenotypes 
associated with loss-of-function mutations in various genes - these include the mycothiol 
biosynthesis genes mshA, mshB and mshD (Xu et al., 2011), and the NADH dehydrogenase 
ndh(Miesel et al., 1998; Vilcheze et al., 2005). While the catalase KatG  has been reported to 
be  necessary for the activation of isoniazid (Heym et al., 1993), we did not see an 
enrichment in the proportion of katG mutants under isoniazid selection, possibly due to a 
pronounced growth defect of katG mutants in Middlebrook 7H9 media. The isoniazid 
sensitivity profile also predicts a few novel mechanisms potentially associated with isoniazid 
resistance – these include the stringent response regulator RelA, genes in sulfur metabolism 
(cysQ, cysG and sirA) and various oxidoreductases (2-oxoglutarate oxidoreductase subunits 
KorA/KorB (Rv2455c/2454c) and the putative oxidoreductase GuaB3). 
Promoter mutations resulting in the overexpression of the alkyl hydroperoxide 
reductase AhpC were previously identified in multiple isoniazid-resistant clinical 
strains(Miesel et al., 1998). Transposon mutations in the ahpC and also the adjacent ahpD 
loci were underrepresented in the isoniazid selected library, suggesting that loss of 
peroxidase and peroxynitrite reductase function may indeed be associated with increased 
isoniazid sensitivity.  
3.4.5 Efflux pumps 
We also aimed to identify the major efflux systems contributing towards resistance 
of the antibiotics tested (Table 3.2). Contrary to our expectations, disruption of individual 
efflux pump genes generally did not affect fitness under the antibiotic concentrations tested. 
While transposon insertions in the ABC transporter membrane protein gene rv1272c were 
underrepresented after meropenem selection, we did not observe any decrease in the MIC 
for meropenem in the rv1272:tn mutant (Table 3.1). Mutant frequencies for rv1747 were 
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significantly reduced under outgrowth in vancomycin, whereas rv1410c insertions were 
underrepresented under selection with vancomycin, rifampicin and meropenem; however, 
both genes have been previously implicated in cell wall biosynthesis (Martinot et al., 2016; 
Spivey et al., 2013)and may thus be contributing to drug resistance in a drug-efflux 
independent manner. 
Table 3.2 – TnSeq data summary for putative efflux pump genes. This list is based on 
previously published lists of putative efflux pump genes (Black et al., 2014; Louw et al., 
2009). Mutations resulting in statistically significant antibiotic sensitivity (log2 Fc <0, q<0.05) 
are highlighted in yellow. 
 
 
  
Gene FC [log2] qval FC [log2] qval FC [log2] qval FC [log2] qval FC [log2] qval Description
rv0037c -0.34 1 -0.59 1 -0.91 1 -1.48 1 0.19 1 integral membrane protein
rv0194 0.04 1 0.07 1 -0.02 1 0.11 1 -0.13 1 transmembrane multidrug efflux pump
mmpL11 1.05 0.014126 -0.29 1 -0.18 1 0.26 1 -0.14 1 transmembrane transporter MmpL11
mmpL3 -3.79 1 -0.63 1 -1.73 1 -3.03 1 -0.04 1 transmembrane transporter MmpL3
iniB -0.08 1 -0.08 1 0.12 1 -0.72 1 0.21 1 isoniazid inducible protein IniB
iniA 0.05 1 0.12 1 0.18 1 -0.94 0.880197 0.00 1 isoniazid inducible protein IniA
iniC 0.04 1 0.26 1 -0.32 1 -0.91 1 0.05 1 isoniazid inducible protein IniC
mmpL4 -0.10 1 -0.12 1 0.95 0.039806 -0.68 0.086673 -0.08 1 transmembrane transporter MmpL4
mmpL5 0.00 1 0.10 1 0.11 1 0.06 1 0.22 1 transmembrane transporter MmpL5
mmpS5 -0.11 1 0.09 1 0.00 1 0.40 1 0.09 1 membrane protein MmpS5
emrB 0.02 1 0.28 1 0.06 1 0.02 1 -0.07 1 multidrug resistance integral membrane efflux protein EmrB
pstB 0.15 1 0.26 1 -0.02 1 -0.02 1 0.03 1 phosphate-transport ABC transporter ATP-binding protein PstB
mmpL13b -0.02 1 -0.05 1 0.13 1 0.22 1 0.10 1 transmembrane transporter MmpL13b
papA3 0.21 1 -0.09 1 -0.03 1 1.09 1 -0.03 1 polyketide synthase associated protein PapA3
rv1218c 0.08 1 0.26 1 -0.07 1 0.31 1 0.04 1 antibiotic transporter ATP-binding protein
rv1250 0.06 1 -0.04 1 0.24 1 0.10 1 -0.05 1 drug:H+ antiporter-2 (14 Spanner) (DHA2) family drug resistance MFS transporter
rv1258c 0.03 1 -0.25 1 0.25 1 0.08 1 0.11 1 H+ antiporter protein
rv1272c 0.22 1 -0.53 1 -1.24 0.027264 0.02 1 0.68 1 ABC transporter membrane protein
rv1273c 0.15 1 -0.69 1 -0.36 1 0.20 1 0.25 1 ABC transporter membrane protein
irtA 0.18 1 -0.08 1 0.83 1 0.43 1 0.86 1 iron-regulated transporter IrtA
irtB 0.06 1 -0.74 1 1.53 1 0.24 1 1.01 0.948299 iron-regulated transporter IrtB
rv1410c -3.07 0 -3.23 0 -1.91 0 -0.75 1 0.32 1 MFS drug efflux transporter P55
rv1456c 0.00 1 0.00 1 0.00 1 1.00 1 -0.32 1 cytochrome C oxidase subunit XV assembly protein
rv1457c 1.91 1 2.78 1 2.13 1 1.56 1 -3.86 1 ABC transporter efflux protein DrrB
rv1458c -0.18 1 -0.22 1 2.58 0.087426 2.23 0.033915 -1.56 0.653063 antibiotic transporter ATP-binding protein
rv1463 0.00 1 -1.09 1 0.00 1 0.00 1 0.00 1 ABC transporter ATP-binding protein
rv1634 0.05 1 0.15 1 0.12 1 0.45 1 0.92 0.601054 drug efflux membrane protein
rv1686c 0.18 1 -0.01 1 -0.26 1 0.18 1 0.23 1 ABC transporter efflux protein DrrB
rv1687c 0.11 1 -0.10 1 0.11 1 -0.08 1 -0.03 1 ABC transporter ATP-binding protein
rv1747 -3.13 0 -0.90 1 0.35 1 1.97 0 -0.13 1 transmembrane ABC transporter ATP-binding protein
bacA -0.17 1 -0.37 1 -0.43 1 0.10 1 0.03 1 drug-transport transmembrane ABC transporter ATP-binding protein BacA
rv1877 -0.01 1 0.12 1 -0.52 1 -0.01 1 0.14 1 drug:H+ antiporter-2 (14 Spanner) (DHA2) family drug resistance MFS transporter
rv2209 -0.08 1 0.00 1 -0.17 1 -0.10 1 0.09 1 integral membrane protein
stp 0.14 1 0.13 1 0.00 1 0.27 1 0.85 1 integral membrane drug efflux protein Stp
rv2459 -0.16 1 0.09 1 0.46 1 0.01 1 0.09 1 drug:H+ antiporter-2 (14 Spanner) (DHA2) family drug resistance MFS transporter
rv2477c 0.00 1 -1.09 1 0.00 1 1.64 1 0.00 1 ChvD family ATP-binding cassette protein
rv2686c -0.02 1 0.25 1 -0.42 1 0.09 1 0.04 1 antibiotic-transport ABC transporter
rv2687c 0.04 1 -0.40 1 -1.16 1 -0.10 1 0.32 1 antibiotic-transport ABC transporter
rv2688c -0.23 1 -0.44 1 -0.97 1 0.06 1 0.23 1 antibiotic-transport ABC transporter
efpA 0.00 1 0.00 1 0.00 1 -0.15 1 -0.32 1 integral membrane efflux protein EfpA
drrA -0.15 1 -0.05 1 0.02 1 0.29 1 -0.07 1 doxorubicin resistance ATP-binding protein DrrA
drrB -0.28 1 -0.15 1 0.03 1 -0.18 1 -0.01 1 doxorubicin resistance ABC transporter permease DrrB
drrC -0.51 1 -0.58 1 -0.04 1 0.22 1 -0.18 1 ABC transporter efflux protein DrrB
mmpL7 -0.44 1 -0.10 1 0.17 1 -0.01 1 -0.21 1 RND superfamily inner membrane transporter MmpL7
rv2994 0.07 1 0.22 1 0.10 1 0.19 1 -0.07 1 integral membrane protein
rv3000 0.21 1 0.07 1 0.97 1 0.32 1 -0.04 1 ABC transporter permease
mmr -0.33 1 0.08 1 0.35 1 0.58 1 -0.81 1 multidrug resistance protein Mmr
whiB7 -0.37 1 -0.11 1 -0.08 1 -0.38 1 0.31 1 transcriptional regulator WhiB-like WhiB7
rv3239c -0.06 1 0.16 1 0.09 1 0.17 1 -0.11 1 drug:H+ antiporter-2 (14 Spanner) (DHA2) family drug resistance MFS transporter
rv3679 0.05 1 -0.23 1 0.43 1 -0.19 1 -1.32 0.111722 anion transporter ATPase
rv3728 -0.13 1 0.11 1 -0.12 1 0.32 1 -0.36 1 drug:H+ antiporter-2 (14 Spanner) (DHA2) family drug resistance MFS transporter
Vancomycin Rifampicin Meropenem Ethambutol Isoniazid
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3.5 Characterization of FecB (Rv3044) 
fecB transposon mutants were strongly underrepresented in libraries selected under 
partially inhibitory concentrations of all the antibiotics tested, suggesting its importance in 
intrinsic antibiotic cross-resistance (Fig. 3.4A, Table 3.3). We thus chose FecB as a follow-up 
study candidate from our antibiotic susceptibility screens. Based on sequence homology, 
FecB has been annotated as a putative iron(III) dicitrate binding lipoprotein similar to the 
substate binding protein in the FecBCDE iron-citrate ABC transporter system in E. coli 
(Banerjee et al., 2016; Braun and Herrmann, 2007; Staudenmaier et al., 1989); however, the 
other components of this system are absent in the Mtb genome, indicating that fecB may be 
an orphaned gene fulfilling a different function. We generated a ΔfecB deletion strain where 
fecB was replaced with a hygromycin resistance cassette, which we confirmed by Southern 
blot analysis (Fig. 3.8). From the ΔfecB mutant, we also generated a complementation strain 
constitutively expressing fecB under the control of the hsp60 promoter. 
Table 3.3 – fecB mutants are predicted to be strongly sensitive to all five antibiotics studied 
in the screen.  Summary of TnSeq data for fecB 
 
 
 
Figure 3.8 Construction of the ΔfecB mutant.  A – Genomic maps of fecB and adjacent genes 
in WT H37Rv Mtb and the fecB deletion strain, showing SacI restriction sites and probe 
binding sites. B- Southern blot of SacI digested genomic DNA from WT H37Rv and ΔfecB 
strains. 
Gene nameFC [log2] qval FC [log2] qval FC [log2] qval FC [log2] qval FC [log2] qval
fecB -6.97 0 -5.81 0 -3.11 0 -3.35 0 -4.68 0
Vancomycin Rifampicin Isoniazid Ethambutol Meropenem
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3.5.1 FecB is important for intrinsic resistance to multiple antibiotics 
We validated the predictions of the TnSeq screen by MIC assays. The MIC for the 
ΔfecB strain was reduced by 16-fold for vancomycin and 4-fold in rifampicin and meropenem, 
however, we did not observe a reduction in MIC of at least 1.5-fold for isoniazid and 
ethambutol (Table 3.1/3.4, Fig 3.5). Despite the lack of a strong MIC shift, the growth rate of 
the ΔfecB mutant was reduced relative to the WT strain under partially inhibitory 
concentrations of isoniazid and ethambutol (Fig. 3.6), confirming the TnSeq predictions of 
reduced ΔfecB fitness. 
Further MIC assays showed that the ΔfecB mutant is hypersensitive to multiple 
antibiotics to varying degrees, and that the increased antibiotic sensitivity could be 
complemented by constitutive expression of fecB from an integrative plasmid (Table 3.4). 
The fold-reduction in antibiotic MIC in the ΔfecB mutant was correlated with antibiotic 
molecular weight (Pearson r = 0.734), suggesting that FecB is important in intrinsic resistance 
to higher molecular weight antibiotics (Fig. 3.9). 
 
Figure 3.9 – The ΔfecB mutant exhibits greater hypersensitivity to higher molecular-weight 
antibiotics.   Correlation plot of the relative reduction in MIC of the ΔfecB mutant versus 
antibiotic molecular weight  
r = 0.734 
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3.5.2 FecB is not likely to be a major iron transporter 
As FecB is annotated as a putative iron (III) dicitrate binding lipoprotein, we tested if 
the ΔfecB mutant exhibited any iron-dependent growth effects. We used the ΔmbtK mutant 
as a positive reference control for deficient iron uptake – the ΔmbtK strain is unable to 
synthesize mycobactins, major siderophores important for iron transport in Mtb, and was 
shown to be impaired in iron scavenging and growth in vitro (Madigan et al., 2015). In growth 
curves using chelated Sauton’s medium as the base medium, the ΔfecB mutant showed 
growth comparable to the WT and complementation strains at ammonium ferric citrate 
concentrations of 0.5µM, 50µM and 500 µM; in contrast, the ΔmbtK mutant was unable to 
grow at 0.5µM of ferric ammonium citrate and was growth defective relative to the WT 
strain at the higher iron concentrations (Fig. 3.10A). We were unable to conclude if the ΔfecB 
mutant was slightly attenuated relative to the WT/complementation strains in the base 
Sauton’s media without iron supplementation because of experimental variability (Fig. 
3.10A/3.10B), this was likely due to variations in residual trace amounts of iron in the base 
media, and also possible carryover of iron from the preculture. However, the WT, ΔfecB, and 
complementation strains all exhibited slow growth in the absence of iron supplementation, 
while the ΔmbtK was completely unable to grow at concentrations below 0.5µM of ferric 
ammonium citrate – this suggested FecB was not as important as the mycobactin pathway in 
iron transport. 
We also performed growth assays using Sauton’s medium supplemented with hemin, 
an iron source that can be taken up by Mtb independently of the mycobactin pathway 
(Owens et al., 2013; Tullius et al., 2011). Hemin supplementation was able to rescue the 
growth defect of the ΔmbtK strain in Sauton’s medium and 7H9 (which contains ammonium 
ferric citrate as an iron source), but did not further improve growth of ΔfecB (Fig. 3.10B, Fig. 
3.10C). We conclude that ΔfecB does not have a significant iron utilization defect under the 
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conditions of the screen (which uses 7H9 as the culture medium), and the increased 
antibiotic susceptibility is not likely to be related to iron deficiency.  
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Figure 3.10 – FecB is not likely to be a major iron transporter.Growth curves of Mtb strains 
under different iron supplementation conditions: A- Sauton’s medium supplemented with 
ammonium ferric citrate (AFC). B- Sauton’s medium supplemented with hemin. C- 
Middlebrook 7H9 media supplemented with hemin 
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3.5.3 The ΔfecB mutant has a more permeable and less lipophilic cell envelope   
Given the large proportion of cell envelope processes represented in the antibiotic-
sensitive mutants predicted by TnSeq, and also the negative interaction between fecB and 
marP, we hypothesized that fecB was also important in determining the integrity of the cell 
envelope. We tested for increased cell envelope permeability in the ΔfecB mutant by the 
ethidium bromide (EtBr) uptake assay (Rodrigues et al., 2015). The ΔfecB mutant exhibited a 
4-5-fold increase in ethidium bromide uptake relative to the WT and complemented strains 
based on fluorescence measurements, suggesting that loss of fecB results in increased cell 
envelope permeability (Fig. 3.11A). To investigate the possibility that the loss of fecB may 
have resulted in greater EtBr uptake due to reduced efflux, we treated the cells with the 
efflux inhibitor verapamil (Fig. 3.11B) – all three strains experienced a 50% increase in EtBr 
uptake, with the ΔfecB mutant still exhibiting a 4-5 fold greater uptake relative to the other 
strains, showing that the increased EtBr uptake in the ΔfecB was independent of verapamil-
sensitive efflux mechanisms, and likely due to increased cell envelope permeability  
To confirm if increased cell envelope permeability could result in increased antibiotic 
uptake, we measured the uptake of fluorescent-tagged vancomycin in the various Mtb 
strains. The ΔfecB mutant exhibited a similar 4-5-fold increase in vancomycin uptake relative 
to the WT and complemented strains, implying that the observed vancomycin sensitivity 
could be attributed to an increase in cell envelope permeability. 
C 
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Figure 3.11 - The ΔfecB mutant exhibits increased uptake of exogenous substrates.  A/B – 
Uptake of ethidium bromide by WT (black), ΔfecB(red) and complemented (blue) strains in 
the absence (A) and presence (B) of 100µg/ml verapamil. Fluorescent emission at 590nm was 
measured at 1min intervals from triplicated wells, and the data shown is representative of 
two independent experiments. C- Uptake of BODIPY-FL tagged vancomycin. A suspension of 
Mtb in PBS/tagged vancomycin was sampled at the timepoints indicated and washed, and 
emission at 538nm normalized to the OD of the washed suspension was measured. 
Datapoints shown are the means of triplicated measurements ± SD and are representative of 
two independent experiments 
 The increase in cell envelope permeability implies a change in cell envelope structure 
and physical properties. Previous studies have indicated that mycobacterial mutants in pknG, 
fbpA and mycolic acid biosynthesis have less hydrophobic cell walls and increased sensitivity 
to multiple antibiotics (Liu and Nikaido, 1999; Nguyen et al., 2005; Wolff and Nguyen, 2012). 
We assayed the cell envelope hydrophobicity of the ΔfecB mutant by the hexadecane 
partition procedure (Etienne et al., 2002; Rosenberg et al., 1980) – the ΔfecB mutant was 
significantly less hydrophobic than the WT strain (but not the complementation strain), 
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suggesting a change in the composition of the cell envelope that could possibly account for 
the increased permeability and antibiotic sensitivity. 
 
Figure 3.12 – The ΔfecB mutant has a less hydrophobic cell envelope. The hydrophobicity of 
the WT, ΔfecB and complementation strains was assessed by the hexadecane partition 
procedure. Triplicate measurements were taken for each strain. 
 
3.5.4 The ΔfecB mutant has a growth defect on solid media that may be cell density 
dependent 
In the process of experimentation, we noticed that the ΔfecB mutant had problems 
forming colonies on solid media. We confirmed this effect by plating spots of various 
dilutions of mid-log phase cultures onto 7H10 media (Fig. 3.13) – there appeared to be a 
density dependent growth defect in the ΔfecB mutant, which failed to grow at spot dilutions 
of ~104 cfu per spot or less. Spot morphology was also altered in the ΔfecB mutant – ΔfecB 
mutant spots had a smoother appearance, in contrast to the reticulated appearance of the 
WT and complementation strain spots and colonies. We did not observe ΔfecB colonies at 
the lower spot concentrations after up to 8 weeks of outgrowth. We tested a variety of 
different conditions to determine if any media specific component might be affecting the 
growth of the ΔfecB mutant. There was no improvement from the removal of potentially 
toxic media components (achieved by the omission of malachite green or oleic acid 
supplementation; and also by the addition of activated charcoal to adsorb unknown toxic 
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agents), supplementation with iron sources (hemin and ferric ammonium citrate) or lowering 
the atmospheric oxygen concentration in the incubator (data not shown). 
 
Figure 3.13 – The ΔfecB mutant is defective for growth on solid media. Volumes of Mtb 
culture containing 101 – 106 cfu were spotted onto 7H10 media. The spot dilutions shown 
here are from after 12 days of outgrowth. 
  The severe growth defect of the ΔfecB mutant on solid media was incongruous with 
the TnSeq data indicating that it was not essential on solid media, and our ability to isolate 
the mutant in the first place. As the plate phenotype that we observed implied cell-density 
dependent ΔfecB mutant growth, we hypothesized that we were able to previously able 
isolate fecB mutants due to the presence of high densities of untransformed bacteria on the 
plate. To recapitulate these conditions, we plated a high density of WT bacteria onto 7H10 
plates containing hygromycin before performing the spot dilutions. This addition of WT 
bacteria was able to rescue the growth defect of the ΔfecB mutant (Fig. 3.14). Treatment 
with culture supernatant was however unable to rescue the growth defect, suggesting that a 
cell-associated component was involved in alleviating the ΔfecB phenotype. We were unable 
to rescue growth with either heat-killed Mtb or lysate obtained from mechanically-disrupted 
cultures; however, WT cells pre-killed by hygromycin could alleviate the growth defect (data 
not shown), suggesting a requirement for intact cells for rescue.  
  
cfu 
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Figure 3.14– The ΔfecB mutant is able to grow on solid media in the presence of WT cells. 
 
1ml of an OD1.0 WT culture (~5x108 cfu) or an equivalent volume of WT culture supernatant 
or 7H9 was spread onto 7H10-hygromycin plates, and different concentrations of ΔfecB and 
complementation strain culture were spotted onto the plate 
 
3.5.5 The ΔfecB mutant is attenuated in vivo 
fecB was previously predicted to be required for in vivo growth (Zhang et al., 2013). 
We infected C57BL/6 mice with the WT, ΔfecB and complementation strains via aerosol; we 
subsequently measured bacterial burdens in the lung and spleen, and also assessed lung 
pathology. 7H10- hygromycin plates pre-treated with WT cells were used in the enumeration 
of ΔfecB colonies. ΔfecB burden in the lung was reduced by at least 2-3 orders of magnitude 
relative to infection with the WT/complementation strains at the d16, d28 and d56 
timepoints; we were also unable to recover ΔfecB lung colonies in half of the mice in the d16, 
d28, and d56 timepoints, indicating either a failure to establish infection or incomplete 
cfu 
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rescue of the plate attenuation phenotype. We did not recover any ΔfecB colonies from the 
spleens (Fig. 3.15A). 
Due to the uncertainty about colony enumeration in the ΔfecB strain, we assessed 
lung pathology as a secondary indicator of strain virulence (Fig. 3.15B-D). Mice infected with 
ΔfecB did not have granulomatous lung lesions at d56 post-infection, indicating reduced 
virulence of the ΔfecB strain.  
 
 
 
  
 
 
(continued) 
 
A 
B C 
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Figure 3.15 – The ΔfecB mutant is attenuated in vivo.  A- Lung and spleen cfu counts from 
mice infected with the WT, ΔfecB and complementation strains. B- Gross lung pathology of 
infected mice. C,D- Hematoxylin and eosin (H&E) staining of lung sections at C- 1x and D- 4x 
magnification 
  
D 
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3.6 Discussion 
3.6.1 The functional role of FecB 
From our screen, we identified fecB to be a gene important in cross-resistance to 
multiple antibiotics. Loss of fecB resulted in increased cell envelope permeability and a slight 
reduction in cell envelope hydrophobicity, suggesting a role for FecB in cell envelope 
structure and integrity. Despite its annotation as an iron transport protein, we did not see 
any major requirement of FecB in the utilization of iron; this may be due to the absence of 
the other components of the ferric-citrate ABC transporter system in the Mtb genome. FecB 
in E. coli has been shown to different species of ferric citrate as well as other trivalent metal 
ion complexes with citrate, and also a variety of tricarboxylic acids in complex or not 
complexed with metal ions (Banerjee et al., 2016). While our studies do not suggest that 
FecB is majorly involved in iron transport, it could possibly be involved in the regulation of 
periplasmic iron concentrations, or alternatively be involved in the transport of other metal 
ions or tricarboxylic acids. The construction of structural mutants of FecB in its ligand binding 
site could potentially help us confirm if its ligand binding activity is important in determining 
the cell envelope structure of Mtb. 
In addition to increased susceptibility to multiple antibiotics, the ΔfecB mutant was 
attenuated in vivo and displayed a density-dependent growth defect on solid media. It is 
unknown at this point why the ΔfecB mutant has such a profound growth defect on plates, 
but we speculate that altered cell envelope properties/composition in the ΔfecB mutant 
might lead to deficiency in colony/biofilm formation, which may be rescued by unknown 
factors secreted by other Mtb cells in a high-density culture. In-depth lipidomic and 
metabolomic analysis may help us identify deficient metabolites in the fecB mutant that may 
inform us on the processes required for colony and biofilm formation. 
Finally, in light of the pleiotropic multi-stress sensitivity phenotypes of other cell 
envelope mutants such as the ΔmarP, it is likely that FecB may also be important in resisting 
 92 
multiple stresses such as low pH, detergent and oxidative/nitrosative stress. Assays 
quantifying bacteriocidal effects on the ΔfecB mutant are currently subject to uncertainty 
due to the difficulty in recovering ΔfecB colonies on solid media. The construction of a 
conditionally-regulated fecB mutant could permit the reliable enumeration of colonies on 
solid media inducing FecB expression, and thus allow bacteriocidal assays to be performed. 
Alternatively, a liquid media based bacterial quantification method such as the most-
probable-number (MPN) assay could be used. Future work involving bacteriocidal 
concentrations of antibiotics could help determine if killing kinetics are accelerated in the 
ΔfecB mutant and whether persister frequency is altered, which could indicate the suitability 
of FecB as a synergistic target potentiating the action of antibiotics. 
3.6.2 Key conclusions of the antibiotic susceptibility screen 
In this study, we used a TnSeq-based approach to identify and rank the genetic 
determinants of Mtb fitness under multiple antibiotic selection pressures. One of the aims of 
our study was to determine if the mechanisms governing antibiotic sensitivity are generally 
antibiotic-specific or largely shared across the different antibiotics. Cell envelope/cell division 
genes featured predominantly amongst the mutants sensitive toward the five antibiotics 
tested, with genes such as fecB, pknG and caeA determining susceptibility to multiple 
antibiotics within the test panel. This could possibly be due to increased cell envelope 
permeability and antibiotic uptake resulting from a compromised cell envelope; alternatively, 
loss of function of these non-essential cell envelope genes could sensitize Mtb to normally 
sub-lethal levels of cell envelope damage induced by antibiotics. While the antibiotics tested 
shared multiple intrinsic resistance mechanisms, we were also able to identify sensitivity 
genes specific to each antibiotic, which could be informative about the mode of action of 
their respective antibiotics. 
The antibiotic susceptibility gene profile of rifampicin was highly similar to that of 
vancomycin and meropenem; this result was somewhat intriguing given that rifampicin 
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inhibits RNA polymerase whereas vancomycin and meropenem act on peptidoglycan 
biosynthesis. The large overlap between the vancomycin/rifampicin sensitivity genes may 
indicate the higher importance of cell envelope permeability in intrinsic resistance to these 
drugs, possibly related to their larger molecular sizes. These results also suggest the 
possibility that sub-inhibitory concentrations of rifampicin may result in cell envelope stress 
that becomes synthetically lethal in combination with the loss of function of certain cell 
envelope genes. Recent studies have shown that point mutations in rpoB, a target gene of 
rifampicin, result in altered fatty acid metabolism(du Preez and Loots, 2012) and profound 
changes in cell wall lipid composition, suggesting that inhibition of RNA polymerase by 
rifampicin is also likely to affect cell envelope structure and integrity. Following this line of 
argument, cell envelope damage could possibly be a major downstream effect of RNA 
polymerase inhibition leading to bacteriocidality, and potential synergistic combinations of 
rifampicin and cell-envelope targeting drugs (in particular the peptidoglycan-actives) could 
lead to more effective anti-TB treatment regimens; this is supported by a recent study 
demonstrating a synergistic effect between rifampicin and carbapenem antibiotics (Kaushik 
et al., 2015).  
We sought to identify the main efflux pump systems contributing to intrinsic 
antibiotic resistance, but contrary to our expectations, we did not observe a major 
requirement for efflux pump genes in the presence of antibiotic selection. There are many 
possible explanations for this conspicuous absence -this may be due to the high level of 
redundancy between the multiple efflux pump systems, which could buffer against the 
effects of single efflux-gene disruption in our TnSeq study. Alternatively, our inability to 
detect significantly important efflux genes may be due to the limitations of our screen – drug 
efflux may be mostly mediated by the few  essential efflux genes (efpA, irtB, rv1463 or 
rv3806c), which are not detectable in our transposon libraries, or that the partly inhibitory 
antibiotic concentrations were insufficient to induce the induction of efflux pumps. Finally, 
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and most simply, it is entirely possible that efflux pumps do not play a key role in intrinsic 
resistance to the antibiotics tested. It was previously noted that treatment with the efflux 
inhibitors reserpine or verapamil did not affect the overall uptake of ofloxacin or rifampicin 
in both replicating and non-replicating Mtb (Piddock et al., 2000; Sarathy et al., 2013). The 
authors of these studies did however suggest the possibility that efficacious induction of 
efflux pumps may be specific to certain drug-resistant strains, and that efflux may be 
comparatively less important in the laboratory H37Rv strain used in the current study. In the 
face of all these possibilities, it is still reasonable to conclude that single-gene inhibition of 
the efflux genes covered by our screen is unlikely to result in any major change in sensitivity 
to the antibiotics tested, and it would thus be unproductive to design inhibitors for individual 
efflux pumps for adjunctive chemotherapy with these drugs. We note that our study does 
not necessarily rule out efflux pumps as important determinants of resistance toward other 
antibiotics, and further screening needs to be done to address this. 
An influential but oft-debated study by Kohanski et al. suggested that the 
bacteriocidal activity of certain antibiotics is due to hydroxyl radical production occurring as a 
consequence of antibiotic-target interaction, resulting in oxidative damage. The study also 
suggested that mechanisms remediating hydroxyl radical damage such as antioxidant 
systems or repair pathways could play an important role in intrinsic antibiotic resistance 
(Kohanski et al., 2007). We did not observe increased sensitivity resulting from mutations in 
the mycothiol biosynthesis pathway, the main antioxidant system in Mtb, as well as in the 
DNA repair genes (e.g. RecA); however, clpB mutants showed an increase in sensitivity to the 
peptidoglycan-targeting drugs vancomycin and meropenem. ClpB is a chaperonin involved in 
the degradation or sequestration of irreversibly oxidized proteins (Vaubourgeix et al., 2015), 
suggesting that the action of vancomycin or meropenem may be associated with increased 
protein damage. Similar to the case of the efflux pumps, the paucity of repair mechanisms 
represented in mutants with increased antibiotic sensitivity may indicate redundancy 
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between repair pathways, an inability of the screen to detect essential repair genes, the 
antibiotic conditions being too low to induce major oxidative damage, or the general non-
involvement of these repair pathways in mitigating damage caused by the antibiotics tested. 
The observation that certain genes affect antibiotic susceptibility in replicating Mtb 
cultures raises the question as to whether they also contribute to antibiotic resistance in 
non-replicating persister populations. Environmental stresses such as hypoxia, oxidative 
stress and nutrient deprivation are known to induce global transcriptional changes resulting 
in altered metabolism, reduced cellular replication, and structural changes to the cell 
envelope, leading to a state of phenotypic drug tolerance (Gengenbacher et al., 2010; 
Nathan and Barry, 2015; Sarathy et al., 2013). It was previously shown that the sulfate 
transport system proteins CysT, CysW, CysA1 and SubI were upregulated under starvation 
conditions (Betts et al., 2002); our observation that transposon insertions in subI-cysTWA1 
(rv2400c-rv2397c) were associated with antibiotic cross-sensitivity suggests a possible 
mechanism by which the upregulation of sulfate utilization pathways may promote antibiotic 
tolerance, by increased synthesis of sulfolipids or other sulfated metabolites that contribute 
to intrinsic resistance. Further characterization of antibiotic-susceptibility determining genes 
may reveal novel mechanisms contributing to phenotypic drug resistance in Mtb. 
3.6.3 Antibiotic susceptibility screen design and troubleshooting 
In order to identify genes determining antibiotic susceptibility, we expanded 
transposon libraries in the presence or absence of partially inhibitory antibiotic 
concentrations close to the MIC, for a period of ~6.5 generations. The rationale for this 
particular screen design is as follows: 
1. By using a partially-inhibitory antibiotic concentration, library selection and 
outgrowth occurs in the same phase of the screen, eliminating the need for a 
secondary outgrowth step. While we could alternatively have performed the screen 
under bacteriocidal conditions and identified mutants with altered killing kinetics, 
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this would have necessitated a secondary outgrowth phase to identify viable 
mutants at the end of the selection period. This could potentially introduce 
selection-independent variation in mutant frequencies in the output libraries, if the 
extent of the outgrowth is not well standardized between the experimental and 
control groups.  Standardization of the outgrowth phase is particularly complicated 
post-antibiotic selection due to delayed recovery of antibiotic-treated cultures and 
potential carryover of antibiotics from the selection culture to the outgrowth plate. A 
secondary outgrowth phase would also result in a loss of library diversity due to 
selection against slow-growing mutants in the outgrowth phase. 
2. Partially inhibitory selection was carried out at an antibiotic concentration close to 
the MIC – this would maximize the selection pressure on the mutant libraries, 
allowing for the identification of a large number of both sensitive and resistant 
mutants. Increasing antibiotic selection pressure would also reduce the extent of 
outgrowth required to obtain a significant change in mutant frequencies. 
3. By reducing the outgrowth duration to 6.5 generations, library diversity is improved 
due to reduced loss of mutants that are growth-defective in culture, even in the 
absence of antibiotic selection. This improves screen coverage and reduces the 
number of “blind-spot” genes that cannot be reliably tested statistically. Secondarily, 
reducing the outgrowth duration ensures that the screens can be completed in 1-2 
weeks, improving experimental efficiency. 
This screen design prioritizes greater genomic coverage, reduced experimental noise and a 
faster execution time; however, the main tradeoff of this design is that it identifies multiple 
trivial hits with minimal impact on antibiotic susceptibility, as defined by standard measures 
of sensitivity such as the MIC or the minimum bacteriocidal concentration (MBC). The 
possible reasons for this non-specificity will be discussed in this section. 
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While our TnSeq screen assesses mutant fitness at a single partially inhibitory 
antibiotic concentration, we chose to assess screen performance based on its ability to 
predict mutants with reduced MICs. The distribution of antibiotics in tuberculosis lesions is 
highly variable (Dartois, 2014; Prideaux et al., 2015), and the MIC is thus more reflective of a 
mutant’s ability to survive and replicate in the diversity of niches in a host undergoing TB 
chemotherapy. Despite the fact that single-concentration mutant fitness and mutant MIC are 
related, they are far from perfectly correlated – multiple hits in this screen and previous 
similar studies (Dorr et al., 2016; Girgis et al., 2009) exhibit no reduction in MICs despite 
showing reduced mutant fitness under specific antibiotic concentrations. It is also possible 
that the significant changes in mutant frequency and the implied changes in antibiotic 
sensitivity may be particular to the culture conditions of the TnSeq screen (e.g. inter-mutant 
competition/cooperation in mixed culture, insufficient recovery time from thawing) and not 
necessarily reproducible in the context of the single-strain MIC assay.  
Nevertheless, our screen demonstrates reasonable predictive ability in the 
identification and ranking of mutants with MIC reductions for vancomycin, rifampicin and 
meropenem. Screen performance was significantly poorer for ethambutol and isoniazid, with 
none of the mutants within our 21 mutant validation panel exhibiting an MIC reduction of 
greater than 1.5-fold for isoniazid. The comparatively poor performance of the isoniazid 
screen could possibly be attributed to the steep Hill slope of the isoniazid Mtb-inhibition 
curve (i.e. the difference between the lowest concentration required to fully inhibit Mtb 
growth and the highest concentration that does not inhibit growth at all is very small), which 
results in major fitness changes over a narrow window of isoniazid concentrations. The 
growth curves of selected mutants under partially inhibitory antibiotic conditions of 
ethambutol and isoniazid (Fig. 3.) illustrate that large changes in growth rates and 
consequently mutant frequencies can occur in spite of miniscule/non-apparent MIC shifts. To 
improve precision in the identification of “non-trivial” hits with significant reductions in MICs, 
 98 
more stringent TnSeq-Fc cutoffs could be imposed, or alternatively, much lower antibiotic 
concentrations could be used to ensure the specific selection of mutants with significant MIC 
reductions. The use of lower antibiotic concentrations would however necessitate a longer 
outgrowth duration, which could reduce library diversity and genomic coverage of the 
screen. 
The problem of trivial hits raises the question as to whether the antibiotic 
susceptibility screen design should be aligned to more clinically relevant measures of 
antibiotic susceptibility. A main aim of this screen was to identify targets that could 
potentiate the activity of existing antibiotics and reduce treatment duration. Relevant 
quantifiers of antibiotic synergy would thus include a reduction in MIC, faster killing kinetics 
and reduced persister populations; particularly under environmental conditions similar to 
those in vivo.  Screening of libraries under bacteriocidal antibiotic concentrations would 
directly address the question of which mutations lead to faster killing and possibly reduced 
persister formation. However, bacteriocidal screens would be more difficult to implement 
due to the above-mentioned problems of reduced library diversity and increased 
experimental noise; in particular, a screen for mutants with reduced persister formation 
would require selection on a much greater mutant population than in this screen to avoid 
bottlenecking effects, due to the low frequency of persisters in the population. At this point, 
it is unknown which screen design performs better in the identification of relevant hits, and 
extensive screen testing and mutant validation would be required to determine optimal 
screen conditions. 
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CHAPTER 4: CONCLUDING REMARKS 
4.1 The convergence of screens 
This work adds two new datasets to the vast body of genetic screen studies in Mtb. If 
one were to step back and look at all the genetic screen data as a whole, he/she might 
notice the recurrence of certain hits across multiple screens. For example, of the 20 other 
acid-susceptible mutants identified in the Vandal screen, 8 were found to be negative 
interactors of marP (Table 2.3), which is not altogether surprising given that they could 
mediate parallel redundant processes contributing to acid resistance. More intriguing are 
hits that span over multiple screens that are seemingly unrelated at first glance –
comparison of a previous in vivo essentiality screen (Zhang et al., 2013) with our antibiotic 
susceptibility screens identifies 20 mutants in common that are more susceptible to at least 
three antibiotics and are also attenuated in vivo; of these 20 genes, 18 are genetic 
interaction partners of marP (the majority of these are negative interactors, with the 
exception of the positively interacting ponA2) (Fig. 4.1). The convergence of these three 
screens points at a functional cluster of genes that is important in the tolerance of the two 
major sources of stress in a clinical setting – antibiotics and the host. 
The unifying theme between these genes appears to their involvement in cell 
envelope processes. As stated in previous sections, we hypothesize the loss of cell envelope 
integrity leads to pleiotropic stress phenotypes, possibly due to increased permeability to 
toxic agents such as antibiotics, weak acids, reactive oxidative/nitrosative species and 
antimicrobial peptides. The interaction of these genes with marP suggests parallel 
functionality between members in this gene cluster, and it would be interesting to verify if 
these mutants share other common phenotypes, such as antibiotic hypersusceptibility 
correlated with antibiotic molecular weight as observed in the ΔfecB mutant. 
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Figure 4.1 – Overlapping hits between in vivo essentiality, antibiotic susceptibility and 
marP genetic interaction screens. A- Overlap of mutants that are significantly more sensitive 
to at least three antibiotics, genetic interaction partners of marP (q<0.05 under the 
resampling test), or required for optimal growth in vivo (based on the criteria defined by 
Zhang et al. 2013, in which mutants are underrepresented 10-fold in vivo relative to an in 
vitro control and are significant under the Mann-Whitney-U (MWU) test at q<0.01, at D10 
and D45 post-aerosol infection). B- List of 18 hits shared between the screens. Detailed 
TnSeq statistics are available in Appendix A2. 
Gene Annotation 
pbpA penicillin-binding protein PbpA 
pssA CDP-diacylglycerol-serine O-phosphatidyltransferase PssA 
rv0472c transcriptional regulator TetR-family 
moeA1 molybdopterin biosynthesis protein MoeA1 
rv1086 short-chain Z-isoprenyl diphosphate synthase 
pimE mannosyltransferase PimE 
rv1566c invasion-associated protein RipD 
secA2 preprotein translocase ATPase subunit SecA2 
ppm1 polyprenol-monophosphomannose synthase Ppm1 
mmpS3 membrane protein MmpS3 
caeA carboxylesterase CaeA 
sigB RNA polymerase sigma factor SigB 
rip1 metalloprotease Rip1 
fecB Fe(III)-dicitrate-binding periplasmic lipoprotein FecB 
rv3193c transmembrane protein 
rv3205c hypothetical protein 
rv3267 hypothetical protein (CpsA related protein) 
ponA2 bifunctional membrane-associated penicillin-binding protein 1A/1B PonA2 
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  The end of many a bacterial genetics study is marked with the tired refrain of “our 
gene may prove to be valuable antibiotic target” – might the genes we have identified be of 
therapeutic value, and if so, what distinguishes them from the multitudes of other potential 
chemotherapeutic options? Based on current drug development paradigms, the answer is a 
resounding “no” – the most ideal antibiotic targets are essential in vitro, and the critical 
weakness of transposon library-based screens is that the vast majority of the genes 
represented in the library are non-essential (with the exception of genes with both 
essential/non-essential genes such as RipA), and are presumably less potent antibiotic 
targets. To advocate for the devil, one could possibly argue the targets we have identified 
may be vulnerable in an in vivo context, and also possess the attractive quality of synergizing 
with existing antibiotic regimens, which may give them an edge over more conventional 
candidates. On a more theoretical note, genetic interaction screens could identify 
synthetically lethal combinations of non-essential targets – for example, a hypothetical 
combination of MarP and FecB inhibitor could have potent anti-mycobacterial activity, if one 
manages to get around the logistical problem of developing two different inhibitors. 
Ultimately, what decides the success of an antibiotic target is not genetics but chemistry, and 
the points raised are moot in the absence of a pharmacologically-suitable inhibitor. 
4.2 The future of genetic screens in Mtb 
At this point in time, TnSeq is one of the more powerful methodologies for high-
throughput genome-wide screening of Mtb mutants, but it is unable to comprehensively 
characterize the genes that are essential in vitro. These essential genes are likely to represent 
critical weak points in the physiology of Mtb, and future genetic screens will need to reach 
past the low-hanging fruit of non-essential genes in order to expose these vulnerabilities. 
The study of essential genes is hindered by the non-viability of gene deletion 
mutants, and requires the construction of viable partial-loss-of-function mutants. 
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Conditional-knockdown systems regulated by transcriptional/proteolytic control (Kim et al., 
2013; Lin et al., 2016) have opened the way for the study of essential Mtb genes; however, 
large collections of these conditionally-regulated mutants need to be constructed and 
amassed to attain high-throughput screening capabilities comparable to that of TnSeq, an 
enormous undertaking that would require at least a few more years (and a lot of money) to 
complete. Recent advances in CRISPR interference (CRISPRi) hint at a possible fast-track for 
the rapid assembly of an essential gene knockdown library in Mtb, it is likely that much more 
optimization is needed to attain effective and reliable knockdown, and to control for possible 
off-target effects (Choudhary et al., 2015; Peters et al., 2016; Singh et al., 2016). The 
realization of a comprehensive knockdown library in Mtb could pave the way for the 
discovery of more complete genetic interaction networks, the identification of specific 
targets of novel antibiotic candidates (Kim et al., 2013), and also targets that synergize with 
existing antibiotic regimens while possessing potent bacteriocidal/bacteriostatic activity 
themselves. 
All in all, this TnSeq study may just be a prelude for the greater things that are yet to 
come. It does however provide some key lessons that may aid in the execution and 
interpretation of future genetic screens encompassing essential genes: 
1. Expect pleiotropy. Our study has shown that there are multiple non-essential genes 
that mediate susceptibility to different antimicrobial agents and stresses, and are 
identified across multiple screens; additionally, the marP screen highlights the fact 
that a single gene can genetically interact with multiple pathways of disparate 
function. We predict that pleiotropy may be even more common in essential genes 
given their physiological importance, and knockdown of these genes may lead to 
broad perturbations across multiple physiological systems, as has been observed in 
mutants of the RNA polymerase gene rpoB (du Preez and Loots, 2012; Lahiri et al., 
2016). The identification of pleiotropic genes is both a blessing and a curse – genes 
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mediating pleiotropic susceptibility to multiple stresses could be potent antibiotic 
targets synergizing with existing antibiotic regimens and host-induced stresses, 
however, the potentially large number of non-specific genetic and chemical-genomic 
interactions could frustrate efforts to identify specific functional gene targets, as 
illustrated in our marP interaction screen. The curation of a list of “usual suspects” 
mediating multiple phenotypes could help narrow down the list of specific targets, 
but might be inherently misleading – a gene may possess the specific function 
targeted by the screen, but may be discarded due to guilt by association with other 
pleiotropic genes 
2. Context is important. Interpretation of data from high-throughput genetic screens is 
not straightforward – this is in part due to the highly-interconnected nature of 
genetic and chemical-genetic interaction networks and gene pleiotropy as described 
above, and also due to the quantification of interactions by simple numerical 
measures that do not necessarily correspond to the aims of the screen; a case in the 
point is our identification of mutants with miniscule shifts in isoniazid MIC, despite 
the large difference in mutant fitness at the single concentration used in the screen. 
Screen data should never be taken at face value on its own, but independently 
verified and interpreted through other screens and experiments. For example, cross-
referencing of multiple genetic/chemical-genomic screens could help identify specific 
and non-specific screen hits, and specific genetic interactions could be revealed by 
supplemental protein-protein interaction screens. 
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CHAPTER 5: MATERIALS AND METHODS 
5.1 Bacteria strains and culture conditions 
M. tuberculosis H37Rv and derivative strains were routinely cultured in Middlebrook 
7H9 medium (BD Difco) supplemented with 0.2% glycerol, 0.05% Tween 80, 0.5% bovine 
serum albumin (Roche), 0.2% dextrose and 0.085% NaCl. The antibiotics hygromycin B 
(50µg/ml), kanamycin (50µg/ml) and zeocin were added to media when selection was 
required. 
The ΔmarP strain was obtained from a previous study (Vandal et al., 2008). Gene 
deletion mutants of rv0812 and fecB were constructed by a recombineering strategy of allelic 
exchange as previously described (Murphy et al., 2015), and confirmed by Southern blotting. 
In the case of the rv0812 mutant, 1µg/ml of PABA or 1µg/ml of D-glutamate/D-alanine 
(Sigma) were added to plate media to rescue auxotrophy. Complementation strains of 
rv0812 and fecB were generated from their respective gene deletions strain by reintroducing 
a copy of rv0812/fecB under the control of the hsp60 promoter into the attL5 site. All 
complementation plasmids were created using Gateway Cloning Technology (Invitrogen). 
Additional mutant strains used in antibiotic susceptibility validation are listed in Table 3.1. 
 
5.2 Transposon library construction 
Mtb transposon libraries were constructed in quadruplicate in the WT H37Rv /ΔmarP 
backgrounds by himar1 mutagenesis as previously described (Long et al., 2015). Briefly, 
100ml mid-log phase Mtb cultures (OD600 ~0.7-1.0) were incubated with 1-2x1011 pfu of 
ΦMycoMarT7 phage(Sassetti et al., 2001) at 37°C for 4h. Cultures were then washed and 
plated on Middlebrook 7H9 media in 1.5% agar supplemented with OADC (BD BBL), 0.5% 
glycerol and 0.05% Tween 80, and incubated for 19 days for the WT strain and 21 days for 
the ΔmarP strain at 37°C, yielding libraries consisting of ~105 mutants each. Libraries was 
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harvested by scraping and stored as frozen stocks in Middlebrook 7H9 media in 15% glycerol 
at -80°C for downstream experiments.  
5.3 TnSeq antibiotic-susceptibility screen 
A WT transposon library frozen stock was thawed and incubated in Middlebrook 7H9 
media for 4 days at 37°C to allow the library to recover to log-phase growth. This library 
starter culture was subcultured into 25ml cultures at a starting OD580 of 0.01, at varying 
antibiotic concentrations including an antibiotic-free control. Cultures were incubated at 
37°C until an OD580 of ~1.0 as to standardize the number of outgrowth generations between 
libraries at approximately 6.5 generations. A partially-inhibitory concentration inhibiting the 
library growth rate to between 60-75% of that of the antibiotic-free library was determined 
for each antibiotic, this concentration was typically between 0.25x-0.5x of the antibiotic MIC; 
the selection concentrations used were 16 µg/ml for vancomycin, 4 ng/ml for rifampicin, 1.2 
µg/ml for meropenem, 20-30 ng/ml for isoniazid and 0.4-0.6 µg/ml for ethambutol. 
5.4 Sequencing of transposon mutant libraries 
Genomic DNA was extracted from selected transposon libraries and mutant 
composition was determined by sequencing amplicons of the transposon-genome junctions 
as previously described (Long et al., 2015). Briefly, genomic DNA was sheared into ~500bp 
fragments by ultrasonication by a Covaris® E220 system, and fragments were subjected to 
end-repair and A-tailing with Taq polymerase, and ligated to T-tailed adapters bearing 
random 7-nucleotide barcodes to distinguish between unique fragments before subsequent 
PCR amplification. Fragments containing transposon-genome junctions were selectively 
enriched in a first PCR amplification, size-selected at a 400-600bp range and amplified in a 
second hemi-nested PCR to add adapter sequences for Illumina® sequencing. PCR amplicons 
were subjected to 75-100bp paired-end sequencing on an Illumina® HiSeq platform and raw 
sequence data was exported to .fastq files for further analysis. 
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5.5 Mapping and quantification of transposon insertions 
Raw sequence data was processed using the TPP tool from the TRANSIT TnSeq 
analysis platform (DeJesus et al., 2015) – transposon genome junctions were mapped to the 
Mtb H37Rv reference genome NC_018143.1 using the Burroughs-Wheeler Aligner (BWA).  To 
account for possible PCR amplication biases, reads corresponding to the same TA site and 
possessing the same 7-nucleotide barcode were considered to be derived from the same 
template, and these duplicate reads were discarded from the final template counts. Gene 
essentiality calls were assigned using a 4-state Hidden Markov Model (DeJesus and Ioerger, 
2013) based on library datasets obtained from 4 independently constructed libraries 
outgrown on 7H9 agar plates (Plate essentiality), and the 13 libraries outgrown in 7H9 used 
as antibiotic-free controls for the TnSeq antibiotic screen (7H9 essentiality). 
5.6 Identification of genes affecting fitness under antibiotic selection 
Genes conditionally affecting fitness in the presence of antibiotic selection were 
identified using the resampling test module in the TRANSIT analysis platform as previously 
described(DeJesus et al., 2015).  Briefly, triplicated libraries outgrown in the presence of 
antibiotics were compared to their corresponding antibiotic-free controls derived from the 
same starter cultures; differences in template-counts between libraries were normalized 
using Trimmed Total Reads (TTR) normalization. Significant differences between the sum of 
read-counts in the antibiotic-free and antibiotic-selected conditions were evaluated by 
comparison to a resampling distribution derived by randomly permutation of the observed 
counts of TA sites within a particular genetic locus among all datasets; p-values were defined 
as the proportion of values within 106 permutations that had a value more extreme than the 
observed experimental result, and these p-values were adjusted for multiple comparisons 
(qval) using the Benjamini-Hochberg procedure. TnSeq fold changes (TnSeq-Fc) were 
computed as log2 transformed ratios of the normalized read-counts between the antibiotic-
selected and antibiotic-free libraries; to facilitate logarithmic transformation, zero-values 
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within the read counts were replaced with a pseudocount corresponding to the detection 
limit of the sequencing data.  
We defined genes having a qval <0.05 from the resampling/permutation test to be 
significant determinants of fitness under antibiotic selection. For antibiotics which had two 
different selection conditions sequenced (isoniazid, ethambutol and meropenem), the higher 
of the two concentrations was used as the reference dataset for downstream analysis due to 
the higher sensitivity in identifying significant loci. 
5.7 Additional data analysis and representation 
Similarity between the various antibiotic-sensitivity profiles was determined based 
on average-linkage clustering of uncentered Pearson correlations with Cluster 3.0(de Hoon et 
al., 2004). Data arrays and cluster trees were visualized using Java Treeview (Saldanha, 2004). 
Overlap between antibiotic sensitivity profiles was quantified in terms of the Jaccard 
index (i.e. the proportion of shared genes over the total number of genes in both profiles, or 
A∩B/A⋃B). Venn diagrams were generated using the Venn Diagrams webtool 
(Universiteit_Gent_Bioinformatics) 
Spearman correlation between MIC-shifts and TnSeq-Fcs were calculated in Prism 
7.0. Numerical data and figures were presented using Microsoft Excel, Prism 7.0 and R. 
5.8 Proteolysis assay for possible MarP substrates 
Gateway Cloning Technology was used to generate episomal plasmids expressing C-
terminal FLAG-tagged versions of Rv0012, Rv0537 and Rv0538, and transformed into WT and 
ΔmarP M. smegmatis mc2155. 
50ml cultures were grown to mid-log phase (OD 0.8-1.2) in Sauton’s medium and 
washed in 1xPBS. Protein lysates were prepared by 3 cycles of mechanical lysis of at 4500rpm 
for 30 seconds each with 0.1mm zirconia/silica beads. The cell wall fraction was obtained by 
centrifuging the toal lysate at 13000rpm at 4⁰C for 60min, and boiled in 10% SDS for 10min 
to solubilize the pellet. Protein concentrations were estimated using the BioRad Lowry assay 
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kit, and approximately 50µg of each sample was loaded and separated on a 15% SDS-PAGE 
gel, and transferred to a nitrocellulose membrane. The Western blot was stained in Odyssey 
blocking buffer with mouse anti-FLAG antibody (Sigma, 1:250) and anti-Dlat (1:10000) as a 
loading control, and visualized using the Odyssey Infra-red Imaging System (LI-COR 
Biosciences) 
5.9  Growth/auxotrophy assays for PABA/D-amino acids 
Growth curves were performed in Middlebrook 7H9 media supplemented with 
either 1µg/ml PABA or 1µg/ml each of D-Ala/D-Glu. Growth curves were also performed in 
defined Sauton’s medium containing 0.05% monobasic potassium phosphate, 0.05% 
magnesium sulfate heptahydrate, 0.2% citric acid, 0.005% ammonium ferric citrate, 0.05% 
ammonium sulfate, 0.0001% zinc sulfate, and 0.05% Tween-80 adjusted to pH 7.4. Growth 
assays on solid media were done on 7H10 media supplemented with 1µg/ml PABA or 1µg/ml 
each of D-Ala/D-Glu.  
5.10 Antibiotic sensitivity assay 
Minimum inhibitory concentrations (MIC) for the various Mtb strains were 
determined using the microbroth dilution technique – Mtb strains were grown to mid-log 
phase (OD580 = 0.6-1.0) and equal volumes of Mtb suspension were dispensed into a 4-fold/2-
fold/1.5-fold dilution series in Middlebrook 7H9 media to a final OD of 0.01-0.025 per well. 
OD580 in each well was measured after 10-14 days of outgrowth, and the MIC90 was 
determined at the concentration of antibiotic at which bacterial growth was inhibited by 90% 
relative to the antibiotic-free control wells. Assays were repeated with a minimum of two 
replicates for each strain. 
5.11 Growth assays in different iron sources 
Strains were grown in iron-defined Sauton’s medium – nominally iron-free Sauton’s 
medium was prepared as described above minus the dicationic salts, adjusted to pH 7.4, 
chelated overnight with 20g/L of Chelex-100 resin (Bio-Rad), filtered and supplemented with 
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, 0.05% magnesium sulfate heptahydrate and 0.0001% zinc sulfate. Media was supplemented 
with varying concentrations of ammonium ferric citrate and hemin as indicated. Similarly, 
growth curves were also performed in 7H9 media with the hemin concentrations indicated. 
5.12 Cell envelope permeability assay 
Cell envelope permeability was determined using the ethidium bromide (EtBr) 
uptake assay as previously described (Rodrigues et al., 2015). Briefly, mid-log phase Mtb 
cultures were washed once in PBS + 0.05% Tween 80, and adjusted to an OD of 0.8 in PBS 
supplemented with 0.4% glucose. 100µl of bacteria were added to triplicate wells in black 96-
well plate with clear bottomed wells (Costar), and an equal volume of 2µg/ml EtBr in 
PBS+0.4% glucose was added to each well to a final EtBr concentration of 1µg/ml and an 
OD580 of 0.4. EtBr fluorescence was measured at an excitation wavelength of 530nm and 
emission wavelength of 590nm at one minute intervals over a course of 60 min. To 
investigate possible effects of efflux inhibition, the experiment was repeated with the 
addition of 100µg/ml of verapamil to the test wells. 
A similar assay was performed to determine permeability to fluorescent-tagged 
vancomycin. Mtb suspensions at an OD580 of 0.4 in PBS+0.4% glucose were incubated with 
2µg/ml of BODIPY-FL® vancomycin (Thermo Scientific), and 200µl sample aliquots were taken 
at the 5,30 and 60min incubation timepoints, washed twice and finally resuspended in 200 µl 
PBS. Fluorescence was measured at an excitation of 485nm and emission at 538nm, and 
normalized to the OD580 of the final suspension to account for cell losses during the washing. 
5.13 Cell envelope hydrophobicity assay 
Cell envelope hydrophobicity was assayed by the hexadecane partition procedure 
(Etienne et al., 2002; Rosenberg et al., 1980) – briefly, mid-log phase cultures of the various 
strains were washed in 1xPBS and adjusted to an OD of 1.0 in PBS. 0.3ml of hexadecane 
(Sigma) was added to 0.9ml of each cell suspension in PBS, vortexed for 10s and left to stand 
for 20min to allow the aqueous/organic phases to separate. The OD of the aqueous phase 
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was measured, and the percentage reduction in OD relative to the input was taken as the 
hydrophobicity index. 
5.14 Solid media spot dilution assays 
Mid-log phase cultures (OD0.8-1.2) were diluted to an OD 0.2, and 10-fold serial 
dilutions were prepared. 10µl of each dilution was spotted  onto solid media, producing 
spots containing between 10-106 cfu each. Solid media tested this way include 7H9 agar, 
7H10 agar supplemented with OADC or fatty-acid free ADN, 7H10 agar with 0.4% activated 
charcoal, 7H10 supplemented with 20µM hemin, 50µM of ammonium ferric citrate or  
20ng/ml mycobactin or Sauton’s media + 1.5% Bacto agar. 
For cell-based plate phenotype rescue experiments, 5x108 cfu of mid-log phase WT 
Mtb in 500µl 7H9 were spread onto 7H10 plates with 50µg/ml hygromycin added, as 
controls, equivalent volumes of mid and late log phase (OD 2.5-3.0) culture supernatant or 
7H9 media were added to plates before the addition of spot dilutions. We also treated plates 
with biomass-equivalent amounts of WT bacteria heat-killed at 80⁰C for 1h, WT lysate 
obtained from 3 cycles of mechanical lysis of at 4500rpm for 30 seconds each with 0.1mm 
zirconia/silica beads or bacteria pre-killed in 100µg/ml hygromycin in 7H9 for a period of 14 
days. 
5.15 Mouse infection 
Female C57BL/6 mice (Jackson Laboratory) were infected with Mtb aerosolized using 
the Glass-Col inhalation exposure system – 5ml each of OD 0.2 single-cell suspensions of the 
WT, ΔfecB and complementation strains were injected into the nebulized, delivering 
approximately 100-200 bacilli per mouse. Four mice were sacrificed at each timepoint - lungs 
were harvested at D1, D16, D28 and D56 post-infection, while spleens were harvested at D28 
and D56 post-infection. Organs were homogenized and plated on 7H10 media to enumerate 
cfus, to permit ΔfecB colony growth, 5x108 cfu  of WT Mtb was spread on each plate prior to 
the application of organ homogenates. To visualize lung pathology, the left lung lobes was 
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obtained on D28/D56 and fixed in 10% formalin in PBS, and subsequently sectioned and 
stained with hematoxylin and eosin (H&E) under standard protocols. All mouse procedures 
were reviewed and approved by the Weill Cornell Medical College Institutional Animal Care 
and Use Committee (IACUC)  
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APPENDICES 
 
APPENDIX A1 – Summary of marP interaction screen data 
APPENDIX A2 – Summary of antibiotic susceptibility screen data  
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